Title: 898 significant and interesting disease-drug links profile1 profile2 corr num1 num2 comb p q s_comparison s_sampleA s_sampleB p_comparison p_sampleA p_sampleB GDS2341.0.2.5 GDS2341.0.3.5 0.9374 579 741 902 0 0 agent untreated Type II IFN agent untreated Types I and II IFNs GDS2221.0.2 GDS2221.0.3 0.9324 1338 970 1557 0 0 agent untreated galectin-1 agent untreated lipopolysaccharide GDS2057.0.1.3 GDS2057.0.2.3 0.9319 133 117 165 1.08305620354162e-73 1.87725211904798e-72 agent control DHT agent control RTI-018 GDS2221.1.2 GDS2221.1.3 0.9186 1258 940 1493 0 0 agent vehicle galectin-1 agent vehicle lipopolysaccharide GDS2213.0.1 GDS2213.0.3 0.9007 1016 1316 1633 0 0 agent untreated 5-aza-dC agent untreated 5-aza-dC plus TSA GDS2221.0.3 GDS2221.1.2 0.8932 970 1258 1584 0 0 agent untreated lipopolysaccharide agent vehicle galectin-1 GDS2617.0.1 GDS2617.0.2 0.8870 119 503 560 2.13570228615889e-189 1.70643703849641e-187 disease state normal non-tumorigenic cancer cell disease state normal tumorigenic cancer cell GDS1956.0.10 GDS1956.0.9 0.8764 2334 2401 3275 0 0 disease state normal dysferlin mutation disease state normal Calpain 3 mutation GDS1321.0.1 GDS1321.0.2 0.8713 1117 2064 2372 0 0 disease state normal Barrett's esophagus disease state normal adenocarcinoma GDS1615.0.1 GDS1615.0.2 0.8623 2228 3399 4035 0 0 disease state normal ulcerative colitis disease state normal Crohn's disease GDS1971.0.1 GDS1971.0.2 0.8411 1356 953 1749 0 0 disease state healthy uncomplicated malaria disease state healthy complicated malaria GDS2341.0.1.4 GDS2341.0.3.4 0.8388 217 494 557 1.14217312200344e-148 5.94920285043056e-147 agent untreated Type I IFN agent untreated Types I and II IFNs GDS1956.0.10 GDS1956.0.11 0.8362 2334 2145 3264 0 0 disease state normal dysferlin mutation disease state normal FKRP mutation GDS2216.0.1.5 GDS715.0.7.18 -0.8260 244 136 380 3.82692837530133e-96 9.86316700798032e-95 agent control LPS agent none 4,5-dianilinophthalimide GDS1956.0.8 GDS1956.0.9 0.8224 3999 2401 4620 0 0 disease state normal Duchenne muscular dystrophy disease state normal Calpain 3 mutation GDS1397.0.1 GDS1397.0.2 0.8219 1060 590 1287 2.3496631694012e-316 4.20666985415052e-314 agent untreated HIV agent untreated TNF-alpha GDS2367.0.1.3 GDS715.0.7.18 0.8214 187 136 323 2.85218703319796e-80 5.59493368236819e-79 agent vehicle estradiol agent none 4,5-dianilinophthalimide GDS1956.0.10 GDS1956.0.7 0.8204 2334 1627 3007 0 0 disease state normal dysferlin mutation disease state normal Becker muscular dystrophy GDS1956.0.11 GDS1956.0.9 0.8193 2145 2401 3313 0 0 disease state normal FKRP mutation disease state normal Calpain 3 mutation GDS1926.0.2.4 GDS1926.0.3.4 0.8170 119 135 192 2.63161116393973e-47 2.5752170873608e-46 agent control LTD4 agent control LTD4 and thrombin GDS2250.0.1 GDS2250.0.3 0.8138 160 232 287 3.83657553958043e-69 6.11248918037675e-68 disease state normal non-basal-like cancer disease state normal basal-like cancer GDS2649.2.5.1 GDS2649.3.5.1 0.8120 1267 599 1485 0 0 disease state uninfected early HIV infection disease state uninfected chronic HIV infection GDS268.0.1 GDS268.0.2 0.8107 375 428 647 4.21067861884922e-152 2.28842556919538e-150 disease state non-obese obese disease state non-obese morbidly obese GDS1956.0.11 GDS1956.0.7 0.8041 2145 1627 2866 0 0 disease state normal FKRP mutation disease state normal Becker muscular dystrophy GDS1956.0.7 GDS1956.0.9 0.8018 1627 2401 3113 0 0 disease state normal Becker muscular dystrophy disease state normal Calpain 3 mutation GDS2367.3.4.1 GDS715.0.7.18 -0.7877 266 136 402 3.56899806190169e-86 7.77795483606633e-85 infection control adenovirus adenovirus carrying estrogen receptor beta agent none 4,5-dianilinophthalimide GDS2118.0.1 GDS2118.0.3 0.7855 934 976 1488 5.35283251989798e-312 9.41904503536409e-310 disease state normal refractory anemia disease state normal refractory anemia with excess blasts GDS2200.0.1 GDS2200.0.2 0.7779 649 1112 1397 9.25616205460981e-284 1.40547869142355e-281 disease state normal actinic keratosis disease state normal squamous cell carcinoma GDS1956.0.10 GDS1956.0.8 0.7777 2334 3999 4765 0 0 disease state normal dysferlin mutation disease state normal Duchenne muscular dystrophy GDS715.0.10.18 GDS715.0.13.18 0.7701 158 274 379 1.32994368901725e-75 2.39580143151519e-74 agent none pergolide methanesulfonate agent none 8-(3-chlorostyryl) caffeine GDS1956.0.6 GDS1956.0.8 0.7685 2160 3999 4798 0 0 disease state normal Emery-Dreifuss muscular dystrophy disease state normal Duchenne muscular dystrophy GDS1617.0.4 GDS1617.0.5 0.7679 185 1981 2047 0 0 agent control MGd/25uM zinc agent control MGd/50uM zinc GDS1617.0.2 GDS1617.0.5 0.7673 221 1981 2018 0 0 agent control 50uM zinc agent control MGd/50uM zinc GDS810.0.2 GDS810.0.3 0.7626 837 903 1464 7.1070161676078e-279 1.04413653399349e-276 disease state control moderate AD disease state control severe AD GDS1956.0.11 GDS1956.0.8 0.7602 2145 3999 4704 0 0 disease state normal FKRP mutation disease state normal Duchenne muscular dystrophy GDS1956.0.7 GDS1956.0.8 0.7514 1627 3999 4558 0 0 disease state normal Becker muscular dystrophy disease state normal Duchenne muscular dystrophy GDS1259.0.1 GDS1956.0.2 0.7475 2867 6836 7773 0 0 disease state normal dermatomyositis disease state normal juvenile dermatomyositis GDS2367.0.2.3 GDS715.2.3.18 0.7469 282 266 545 2.69178280659249e-98 7.17040105749825e-97 agent vehicle tamoxifen agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1956.0.2 GDS1956.0.6 0.7460 6836 2160 7209 0 0 disease state normal juvenile dermatomyositis disease state normal Emery-Dreifuss muscular dystrophy GDS2367.0.2.3 GDS715.0.3.18 0.7436 282 592 864 7.40592700088734e-153 4.05937300056917e-151 agent vehicle tamoxifen agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2216.0.1.5 GDS2367.0.1.3 0.7403 244 187 427 2.66172048488259e-75 4.76590925712305e-74 agent control LPS agent vehicle estradiol GDS2216.0.1.5 GDS715.0.8.16 -0.7350 244 109 351 7.53435776896041e-61 1.00768949001395e-59 agent control LPS agent none 1,10-phenanthroline GDS1956.0.2 GDS1956.0.8 0.7306 6836 3999 7807 0 0 disease state normal juvenile dermatomyositis disease state normal Duchenne muscular dystrophy GDS1574.8.9.11 GDS715.2.3.18 0.7256 567 266 830 1.46508280991248e-136 6.56699525391548e-135 agent control endotoxin agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2367.3.4.1 GDS2617.0.1 -0.7246 266 119 382 2.06339380004306e-63 2.91599085591828e-62 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal non-tumorigenic cancer cell GDS2649.3.5.1 GDS2649.4.5.1 0.7240 599 175 698 2.35236901197532e-114 7.94799695879262e-113 disease state uninfected chronic HIV infection disease state uninfected non-progressive HIV infection GDS2367.0.1.3 GDS715.2.3.18 0.7232 187 266 445 3.20990061133291e-73 5.51280413515052e-72 agent vehicle estradiol agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.0.10.18 GDS715.0.12.18 0.7220 158 131 261 2.54046031693044e-43 2.25018878775626e-42 agent none pergolide methanesulfonate agent none 5-fluorouracil GDS715.0.13.18 GDS715.2.10.18 0.7215 274 132 366 4.51891195722348e-60 5.9533594772391e-59 agent none 8-(3-chlorostyryl) caffeine agent negative control pergolide methanesulfonate GDS1574.8.9.11 GDS2216.0.1.5 0.7201 567 244 802 4.12100296437656e-129 1.68571667658774e-127 agent control endotoxin agent control LPS GDS1956.0.1 GDS1956.0.2 0.7194 4393 6836 7955 0 0 disease state normal acute quadriplegic myopathy disease state normal juvenile dermatomyositis GDS715.0.7.18 GDS715.0.8.16 -0.7174 136 109 242 1.51070019222782e-39 1.21133172103396e-38 agent none 4,5-dianilinophthalimide agent none 1,10-phenanthroline GDS1574.8.9.11 GDS715.0.14.18 0.7170 567 141 704 4.01725141309766e-112 1.31378357837166e-110 agent control endotoxin agent none R-(-)-apomorphine HCl GDS1574.8.9.11 GDS715.0.3.18 0.7164 567 592 1142 1.96324421628179e-180 1.44492038308682e-178 agent control endotoxin agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2367.0.1.3 GDS715.2.6.18 0.7164 187 582 762 6.15310374016087e-121 2.28285018688262e-119 agent vehicle estradiol agent negative control 16-ketoestradiol GDS1617.0.2 GDS1617.0.4 0.7158 221 185 367 6.93657248301503e-59 8.90603874162226e-58 agent control 50uM zinc agent control MGd/25uM zinc GDS2216.0.1.5 GDS715.2.3.18 -0.7156 244 266 506 1.43920850086102e-80 2.83910908383498e-79 agent control LPS agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2367.0.2.3 GDS715.0.7.18 0.7125 282 136 415 1.56076963404465e-65 2.30977530890102e-64 agent vehicle tamoxifen agent none 4,5-dianilinophthalimide GDS2250.0.1 GDS2367.3.4.1 -0.7054 160 266 403 6.49994963567666e-62 8.90141505909014e-61 disease state normal non-basal-like cancer infection control adenovirus adenovirus carrying estrogen receptor beta GDS1574.8.9.10 GDS2367.0.1.3 -0.7050 360 187 541 1.79349890307661e-82 3.66041820594451e-81 agent control endotoxin agent vehicle estradiol GDS2367.0.2.3 GDS715.2.6.18 0.7023 282 582 852 1.36900453179651e-127 5.49057773658675e-126 agent vehicle tamoxifen agent negative control 16-ketoestradiol GDS2367.3.4.1 GDS715.2.6.18 -0.7018 266 582 839 2.04345383602867e-125 8.0118941099804e-124 infection control adenovirus adenovirus carrying estrogen receptor beta agent negative control 16-ketoestradiol GDS2250.0.1 GDS2367.0.2.3 0.7014 160 282 409 7.93786608260201e-62 1.08474272100719e-60 disease state normal non-basal-like cancer agent vehicle tamoxifen GDS2367.3.4.1 GDS2635.0.2 -0.7013 266 263 526 4.69395630492718e-79 9.00249626359955e-78 infection control adenovirus adenovirus carrying estrogen receptor beta disease state lobular control invasive lobular carcinoma GDS1375.0.1 GDS1375.0.2 0.7008 2646 4896 5462 0 0 disease state normal benign nevi disease state normal malignant melanoma GDS2250.0.1 GDS2367.0.1.3 0.7007 160 187 323 5.39895792766683e-49 5.48619515907396e-48 disease state normal non-basal-like cancer agent vehicle estradiol GDS1259.0.1 GDS1956.0.1 0.7000 2867 4393 6368 0 0 disease state normal dermatomyositis disease state normal acute quadriplegic myopathy GDS2367.3.4.1 GDS2635.0.3 -0.6977 266 300 558 1.40562854958024e-82 2.87336984199691e-81 infection control adenovirus adenovirus carrying estrogen receptor beta disease state lobular control invasive ductal carcinoma GDS2367.0.1.3 GDS2635.0.2 0.6976 187 263 447 1.99851436582464e-66 3.00966185996521e-65 agent vehicle estradiol disease state lobular control invasive lobular carcinoma GDS1574.8.9.10 GDS2367.3.4.1 0.6975 360 266 619 2.30376061124027e-91 5.51128137563833e-90 agent control endotoxin infection control adenovirus adenovirus carrying estrogen receptor beta GDS2190.0.1 GDS810.0.2 0.6964 163 837 944 6.97265200220465e-138 3.17717451190443e-136 disease state control bipolar disorder disease state control moderate AD GDS715.0.12.18 GDS715.0.13.18 0.6948 131 274 370 1.25014885571395e-54 1.45358159455981e-53 agent none 5-fluorouracil agent none 8-(3-chlorostyryl) caffeine GDS1956.0.2 GDS1956.0.5 0.6932 6836 2945 7534 0 0 disease state normal juvenile dermatomyositis disease state normal fascioscapulohumeral muscular dystrophy GDS266.0.1.2 GDS715.0.8.16 0.6929 407 109 512 1.8352437837955e-74 3.23194941244034e-73 disease state no atopy atopy agent none 1,10-phenanthroline GDS1392.0.1 GDS1392.0.2 0.6911 413 732 1002 3.59266523562868e-143 1.7510493931848e-141 disease state normal rheumatoid arthritis, on methotrexate disease state normal myelodysplastic syndrome GDS1956.0.5 GDS1956.0.6 0.6879 2945 2160 4050 0 0 disease state normal fascioscapulohumeral muscular dystrophy disease state normal Emery-Dreifuss muscular dystrophy GDS1956.0.1 GDS1956.0.6 0.6840 4393 2160 5255 0 0 disease state normal acute quadriplegic myopathy disease state normal Emery-Dreifuss muscular dystrophy GDS2367.0.1.3 GDS2617.0.1 0.6826 187 119 300 1.73476523985438e-42 1.50639460878996e-41 agent vehicle estradiol disease state normal non-tumorigenic cancer cell GDS2216.0.1.5 GDS2367.0.2.3 0.6817 244 282 521 1.89429974684944e-72 3.20789795923634e-71 agent control LPS agent vehicle tamoxifen GDS1259.0.1 GDS1956.0.6 0.6773 2867 2160 4394 0 0 disease state normal dermatomyositis disease state normal Emery-Dreifuss muscular dystrophy GDS1574.8.9.10 GDS2367.0.2.3 -0.6769 360 282 632 6.7867644699129e-86 1.47217030586861e-84 agent control endotoxin agent vehicle tamoxifen GDS715.0.12.18 GDS715.2.10.18 0.6736 131 132 240 4.29989071576897e-33 2.8668722005684e-32 agent none 5-fluorouracil agent negative control pergolide methanesulfonate GDS2341.0.1.4 GDS2341.0.2.4 0.6731 217 300 409 2.73947123786017e-55 3.23906993609862e-54 agent untreated Type I IFN agent untreated Type II IFN GDS1331.0.1 GDS1331.0.2 0.6724 1070 3398 3983 0 0 disease state normal presymptomatic disease state normal symptomatic GDS2367.0.1.3 GDS2635.0.3 0.6722 187 300 479 2.88959082086315e-64 4.16032674164686e-63 agent vehicle estradiol disease state lobular control invasive ductal carcinoma GDS2216.0.1.5 GDS2367.3.4.1 -0.6709 244 266 501 8.40248779130971e-67 1.27447210246788e-65 agent control LPS infection control adenovirus adenovirus carrying estrogen receptor beta GDS2367.0.2.3 GDS2635.0.3 0.6692 282 300 571 2.07836755477116e-75 3.73006978763397e-74 agent vehicle tamoxifen disease state lobular control invasive ductal carcinoma GDS2367.0.2.3 GDS2635.0.2 0.6677 282 263 540 5.65140364385828e-71 9.30727269620204e-70 agent vehicle tamoxifen disease state lobular control invasive lobular carcinoma GDS2367.0.2.3 GDS2617.0.1 0.6671 282 119 395 3.38096989833527e-52 3.7055960661724e-51 agent vehicle tamoxifen disease state normal non-tumorigenic cancer cell GDS1956.0.3 GDS1956.0.6 0.6661 4453 2160 5285 0 0 disease state normal amyotophic lateral sclerosis disease state normal Emery-Dreifuss muscular dystrophy GDS1574.8.9.11 GDS715.2.6.18 0.6652 567 582 1115 2.20957474727907e-143 1.07967132158911e-141 agent control endotoxin agent negative control 16-ketoestradiol GDS2118.0.1 GDS2118.0.2 0.6648 934 2118 2554 0 0 disease state normal refractory anemia disease state normal refractory anemia with ringed sideroblasts GDS715.0.10.18 GDS715.0.11.18 0.6625 158 183 311 1.14717672856744e-40 9.49617381601987e-40 agent none pergolide methanesulfonate agent none scopolamine methyl bromide GDS2216.0.1.5 GDS2341.0.1.5 0.6623 244 136 380 2.49373084823419e-49 2.55086009063502e-48 agent control LPS agent untreated Type I IFN GDS2216.0.1.5 GDS2635.0.2 -0.6608 244 263 504 1.4937065999341e-64 2.16271810061185e-63 agent control LPS disease state lobular control invasive lobular carcinoma GDS2635.0.2 GDS715.2.3.18 -0.6602 263 266 524 6.81275436692199e-67 1.03538456516017e-65 disease state lobular control invasive lobular carcinoma agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.0.11.18 GDS715.0.13.18 0.6598 183 274 402 1.37356752220139e-51 1.48244662212703e-50 agent none scopolamine methyl bromide agent none 8-(3-chlorostyryl) caffeine GDS2367.3.4.1 GDS715.2.3.18 -0.6593 266 266 521 2.7865720458341e-66 4.1845676161477e-65 infection control adenovirus adenovirus carrying estrogen receptor beta agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2649.2.5.1 GDS2649.4.5.1 0.6579 1267 175 1348 5.84160099554648e-168 3.77432347601386e-166 disease state uninfected early HIV infection disease state uninfected non-progressive HIV infection GDS2367.3.4.2 GDS715.0.3.18 -0.6561 691 592 1251 7.20431220781199e-155 4.03065258731587e-153 infection control adenovirus adenovirus carrying estrogen receptor beta agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS651.0.1 GDS651.0.2 0.6545 4221 2231 5187 0 0 disease state normal idiopathic dilated disease state normal ischemic GDS1574.8.9.10 GDS715.0.8.16 0.6526 360 109 461 2.78502990241881e-57 3.44782726145722e-56 agent control endotoxin agent none 1,10-phenanthroline GDS715.0.11.18 GDS715.2.10.18 0.6474 183 132 296 1.49339742990603e-36 1.10032942738291e-35 agent none scopolamine methyl bromide agent negative control pergolide methanesulfonate GDS2216.0.1.5 GDS715.0.14.18 -0.6472 244 141 380 1.77114834935495e-46 1.69780023061322e-45 agent control LPS agent none R-(-)-apomorphine HCl GDS715.0.8.16 GDS715.2.3.18 -0.6445 109 266 372 4.76748367774624e-45 4.41661422083331e-44 agent none 1,10-phenanthroline agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1956.0.3 GDS1956.0.5 0.6398 4453 2945 5758 0 0 disease state normal amyotophic lateral sclerosis disease state normal fascioscapulohumeral muscular dystrophy GDS2367.0.1.3 GDS715.0.8.16 0.6369 187 109 290 2.13106840321873e-34 1.47674038575606e-33 agent vehicle estradiol agent none 1,10-phenanthroline GDS715.0.11.18 GDS715.2.13.18 0.6352 183 317 477 2.95273187655227e-55 3.48961515030018e-54 agent none scopolamine methyl bromide agent negative control 8-(3-chlorostyryl) caffeine GDS2216.0.1.5 GDS715.0.3.18 -0.6343 244 592 821 1.26218788680195e-93 3.12639806492797e-92 agent control LPS agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2367.0.1.3 GDS715.0.3.18 0.6340 187 592 759 1.42168966664067e-86 3.12484110122804e-85 agent vehicle estradiol agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.0.7.18 GDS715.2.3.18 -0.6318 136 266 384 3.54604830039421e-44 3.21315309414933e-43 agent none 4,5-dianilinophthalimide agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2216.0.1.5 GDS715.2.6.18 -0.6300 244 582 812 5.07098162357702e-91 1.20675477834277e-89 agent control LPS agent negative control 16-ketoestradiol GDS715.0.11.18 GDS715.2.3.18 -0.6288 183 266 441 6.52194537117495e-50 6.76757474562395e-49 agent none scopolamine methyl bromide agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1326.2.3.1 GDS2367.3.4.1 0.6287 181 266 439 1.13158644011957e-49 1.16626563364313e-48 agent control E2 infection control adenovirus adenovirus carrying estrogen receptor beta GDS2367.0.2.3 GDS715.0.6.18 0.6286 282 1378 1634 2.12960146960559e-180 1.56586000505811e-178 agent vehicle tamoxifen agent none 16-ketoestradiol GDS1574.8.9.12 GDS1971.0.1 0.6284 2152 1356 3178 0 0 agent control endotoxin disease state healthy uncomplicated malaria GDS2216.0.1.5 GDS2617.0.1 -0.6268 244 119 358 1.77835442564411e-40 1.464147266166e-39 agent control LPS disease state normal non-tumorigenic cancer cell GDS2367.3.4.1 GDS715.0.14.18 -0.6267 266 141 403 2.32359736109734e-45 2.17048049313054e-44 infection control adenovirus adenovirus carrying estrogen receptor beta agent none R-(-)-apomorphine HCl GDS2635.0.2 GDS715.0.3.18 -0.6254 263 592 842 1.39471658030858e-92 3.40428217040808e-91 disease state lobular control invasive lobular carcinoma agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1574.8.9.11 GDS715.0.7.18 0.6225 567 136 694 1.0562872828482e-75 1.90528047020268e-74 agent control endotoxin agent none 4,5-dianilinophthalimide GDS1392.0.1 GDS2367.3.4.1 -0.6224 413 266 672 2.52510366991982e-73 4.3464044760083e-72 disease state normal rheumatoid arthritis, on methotrexate infection control adenovirus adenovirus carrying estrogen receptor beta GDS1259.0.1 GDS1956.0.8 0.6220 2867 3999 5438 0 0 disease state normal dermatomyositis disease state normal Duchenne muscular dystrophy GDS1956.0.6 GDS1956.0.9 0.6216 2160 2401 3715 0 0 disease state normal Emery-Dreifuss muscular dystrophy disease state normal Calpain 3 mutation GDS2617.0.1 GDS715.2.3.18 -0.6212 119 266 381 4.89813901563241e-42 4.19746235734776e-41 disease state normal non-tumorigenic cancer cell agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.0.11.18 GDS715.2.6.18 -0.6200 183 582 755 2.19289289167385e-81 4.39058461303006e-80 agent none scopolamine methyl bromide agent negative control 16-ketoestradiol GDS1956.0.1 GDS1956.0.3 0.6160 4393 4453 6593 0 0 disease state normal acute quadriplegic myopathy disease state normal amyotophic lateral sclerosis GDS266.0.1.2 GDS715.0.3.18 0.6156 407 592 983 1.38029959223175e-103 3.97460932086617e-102 disease state no atopy atopy agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2617.0.1 GDS715.0.7.18 -0.6149 119 136 252 1.33608851377748e-27 7.50840413456536e-27 disease state normal non-tumorigenic cancer cell agent none 4,5-dianilinophthalimide GDS715.0.14.18 GDS715.2.10.18 0.6147 141 132 263 1.01069270714652e-28 5.9099397034195e-28 agent none R-(-)-apomorphine HCl agent negative control pergolide methanesulfonate GDS2635.0.2 GDS715.2.6.18 -0.6141 263 582 834 1.3342057490486e-87 2.98279904781903e-86 disease state lobular control invasive lobular carcinoma agent negative control 16-ketoestradiol GDS2216.0.1.5 GDS715.0.11.18 -0.6090 244 183 423 2.7318320566703e-44 2.48209309250301e-43 agent control LPS agent none scopolamine methyl bromide GDS2635.0.2 GDS715.0.8.16 -0.6085 263 109 372 4.72710852966536e-39 3.74260704074594e-38 disease state lobular control invasive lobular carcinoma agent none 1,10-phenanthroline GDS2367.3.4.1 GDS266.0.1.2 0.6073 266 407 667 1.81275533178547e-68 2.84977362417191e-67 infection control adenovirus adenovirus carrying estrogen receptor beta disease state no atopy atopy GDS2367.3.4.2 GDS715.0.6.18 -0.6067 691 1378 1990 2.10919656576325e-200 1.86209505170912e-198 infection control adenovirus adenovirus carrying estrogen receptor beta agent none 16-ketoestradiol GDS2250.0.1 GDS2617.0.2 0.6048 160 503 618 6.50743590336349e-63 9.09695608214053e-62 disease state normal non-basal-like cancer disease state normal tumorigenic cancer cell GDS1956.0.2 GDS1956.0.3 0.6047 6836 4453 8122 0 0 disease state normal juvenile dermatomyositis disease state normal amyotophic lateral sclerosis GDS2367.0.2.3 GDS715.0.14.18 0.6031 282 141 422 3.73805116356308e-43 3.29709741767558e-42 agent vehicle tamoxifen agent none R-(-)-apomorphine HCl GDS2118.0.2 GDS2118.0.3 0.6026 2118 976 2661 7.90114855553977e-263 1.05692987758814e-260 disease state normal refractory anemia with ringed sideroblasts disease state normal refractory anemia with excess blasts GDS2367.0.2.3 GDS715.0.8.16 0.6018 282 109 389 1.09069719191261e-39 8.78263561564833e-39 agent vehicle tamoxifen agent none 1,10-phenanthroline GDS1574.8.9.10 GDS715.0.11.18 0.6012 360 183 535 6.9811355088668e-54 7.96821325011577e-53 agent control endotoxin agent none scopolamine methyl bromide GDS1956.0.1 GDS1956.0.8 0.6001 4393 3999 6569 0 0 disease state normal acute quadriplegic myopathy disease state normal Duchenne muscular dystrophy GDS2635.0.2 GDS715.0.7.18 -0.5996 263 136 393 9.94451634932882e-40 8.01769975926507e-39 disease state lobular control invasive lobular carcinoma agent none 4,5-dianilinophthalimide GDS2367.0.2.3 GDS715.0.11.18 0.5983 282 183 463 2.7156815545537e-46 2.59240393297774e-45 agent vehicle tamoxifen agent none scopolamine methyl bromide GDS266.0.1.2 GDS715.2.3.18 0.5977 407 266 666 9.63990372975569e-66 1.43238703004983e-64 disease state no atopy atopy agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2367.0.1.3 GDS266.0.1.2 -0.5969 187 407 592 2.00824219267681e-58 2.54741807032222e-57 agent vehicle estradiol disease state no atopy atopy GDS2367.0.1.3 GDS715.0.14.18 0.5954 187 141 321 3.55461537079046e-32 2.30732728031374e-31 agent vehicle estradiol agent none R-(-)-apomorphine HCl GDS2250.0.3 GDS2367.3.4.1 -0.5948 232 266 468 4.06437647464708e-46 3.86668977745707e-45 disease state normal basal-like cancer infection control adenovirus adenovirus carrying estrogen receptor beta GDS2142.0.1 GDS2367.0.1.3 0.5924 226 187 411 2.71532835304879e-40 2.22261801446127e-39 disease state normal mild cystic fibrosis agent vehicle estradiol GDS715.2.10.18 GDS715.2.12.18 0.5911 132 117 226 1.10254417700921e-22 5.1949945092657e-22 agent negative control pergolide methanesulfonate agent negative control 5-fluorouracil GDS715.0.10.18 GDS715.0.14.18 0.5906 158 141 286 2.80199046205293e-28 1.61301751581312e-27 agent none pergolide methanesulfonate agent none R-(-)-apomorphine HCl GDS2367.3.4.1 GDS715.0.8.16 -0.5898 266 109 371 3.89626669307037e-36 2.84098076765255e-35 infection control adenovirus adenovirus carrying estrogen receptor beta agent none 1,10-phenanthroline GDS715.0.11.18 GDS715.0.8.16 -0.5897 183 109 292 9.71424792662005e-29 5.68399364975067e-28 agent none scopolamine methyl bromide agent none 1,10-phenanthroline GDS1574.8.9.10 GDS2617.0.1 0.5889 360 119 475 1.1231787450779e-45 1.05776441756271e-44 agent control endotoxin disease state normal non-tumorigenic cancer cell GDS1392.0.1 GDS2367.0.1.3 0.5870 413 187 596 1.79210440400525e-56 2.17865961963383e-55 disease state normal rheumatoid arthritis, on methotrexate agent vehicle estradiol GDS1392.0.1 GDS2367.0.2.3 0.5858 413 282 687 1.56503553357745e-64 2.26535523522804e-63 disease state normal rheumatoid arthritis, on methotrexate agent vehicle tamoxifen GDS1259.0.1 GDS1956.0.5 0.5849 2867 2945 5044 0 0 disease state normal dermatomyositis disease state normal fascioscapulohumeral muscular dystrophy GDS715.2.10.18 GDS715.2.13.18 0.5846 132 317 415 2.09695527262609e-39 1.6749564542074e-38 agent negative control pergolide methanesulfonate agent negative control 8-(3-chlorostyryl) caffeine GDS1353.0.1.2 GDS715.0.6.18 0.5838 1304 1378 2530 4.49743663933665e-231 5.05078485958893e-229 agent control dexamethasone agent none 16-ketoestradiol GDS1574.8.9.10 GDS2635.0.2 0.5823 360 263 615 4.15439334774769e-57 5.12453787146195e-56 agent control endotoxin disease state lobular control invasive lobular carcinoma GDS2367.0.2.3 GDS266.0.1.2 -0.5823 282 407 678 8.55531663784597e-63 1.19315890085753e-61 agent vehicle tamoxifen disease state no atopy atopy GDS1574.8.9.11 GDS715.0.6.18 0.5817 567 1378 1855 1.99428328080178e-168 1.29341354532464e-166 agent control endotoxin agent none 16-ketoestradiol GDS1259.0.1 GDS1956.0.7 0.5796 2867 1627 3948 0 0 disease state normal dermatomyositis disease state normal Becker muscular dystrophy GDS2250.0.1 GDS2635.0.3 0.5793 160 300 420 5.19431977897739e-39 4.10849946468117e-38 disease state normal non-basal-like cancer disease state lobular control invasive ductal carcinoma GDS2367.0.1.3 GDS715.0.11.18 0.5782 187 183 365 6.03288643678726e-34 4.12612462500946e-33 agent vehicle estradiol agent none scopolamine methyl bromide GDS2118.0.3 GDS2397.0.1 0.5777 976 580 1355 1.86232932007034e-121 6.9495795125091e-120 disease state normal refractory anemia with excess blasts disease state normal idiopathic myelofibrosis GDS1392.0.1 GDS715.0.8.16 -0.5767 413 109 519 2.44953035982077e-47 2.39932557710358e-46 disease state normal rheumatoid arthritis, on methotrexate agent none 1,10-phenanthroline GDS2635.0.3 GDS715.2.3.18 -0.5763 300 266 557 1.32101259493954e-50 1.39253760863526e-49 disease state lobular control invasive ductal carcinoma agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS266.0.1.2 GDS715.2.6.18 0.5742 407 582 970 3.64296541759016e-86 7.93802909760044e-85 disease state no atopy atopy agent negative control 16-ketoestradiol GDS2250.0.3 GDS2367.0.2.3 0.5731 232 282 466 4.91437396846674e-42 4.21090616941617e-41 disease state normal basal-like cancer agent vehicle tamoxifen GDS715.0.12.18 GDS715.0.9.18 0.5731 131 3151 3228 2.97247941975593e-281 4.44769248913832e-279 agent none 5-fluorouracil agent none 5-fluorouridine GDS715.2.12.18 GDS715.2.13.18 0.5730 117 317 410 3.76698995861013e-37 2.8219577767718e-36 agent negative control 5-fluorouracil agent negative control 8-(3-chlorostyryl) caffeine GDS2200.0.2 GDS2418.0.1 0.5721 1112 2548 3140 1.77522682256933e-272 2.49160098965828e-270 disease state normal squamous cell carcinoma disease state control vulvar intraepithelial neoplasia GDS2142.0.1 GDS2367.0.2.3 0.5711 226 282 505 4.73453749094621e-45 4.38688460996747e-44 disease state normal mild cystic fibrosis agent vehicle tamoxifen GDS1956.0.1 GDS1956.0.5 0.5671 4393 2945 5833 0 0 disease state normal acute quadriplegic myopathy disease state normal fascioscapulohumeral muscular dystrophy GDS2617.0.2 GDS2635.0.3 0.5669 503 300 775 4.24439667089473e-67 6.47801818383232e-66 disease state normal tumorigenic cancer cell disease state lobular control invasive ductal carcinoma GDS266.0.1.2 GDS715.0.14.18 0.5669 407 141 541 2.54038442501426e-47 2.48641937592985e-46 disease state no atopy atopy agent none R-(-)-apomorphine HCl GDS1259.0.1 GDS1956.0.11 0.5665 2867 2145 4254 0 0 disease state normal dermatomyositis disease state normal FKRP mutation GDS2190.0.1 GDS810.0.3 0.5641 163 903 1024 4.3722604303303e-87 9.69734137254313e-86 disease state control bipolar disorder disease state control severe AD GDS2250.0.3 GDS2367.0.1.3 0.5640 232 187 383 1.51982100933399e-33 1.02804777100655e-32 disease state normal basal-like cancer agent vehicle estradiol GDS1062.2.3.0 GDS2367.3.4.1 0.5637 483 266 747 7.17093055489558e-64 1.0240176926305e-62 disease state no metastasis metastasis infection control adenovirus adenovirus carrying estrogen receptor beta GDS1956.0.11 GDS1956.0.6 0.5613 2145 2160 3595 1.34006042658408e-297 2.21143413804986e-295 disease state normal FKRP mutation disease state normal Emery-Dreifuss muscular dystrophy GDS1353.0.1.2 GDS1574.8.9.11 -0.5612 1304 567 1806 2.22955468576198e-150 1.18536156866864e-148 agent control dexamethasone agent control endotoxin GDS2635.0.3 GDS715.2.6.18 -0.5606 300 582 864 1.16327074286141e-72 1.97820632593773e-71 disease state lobular control invasive ductal carcinoma agent negative control 16-ketoestradiol GDS2142.0.1 GDS2635.0.2 -0.5579 226 263 487 3.46664853866744e-41 2.90794839907804e-40 disease state normal mild cystic fibrosis disease state lobular control invasive lobular carcinoma GDS2367.3.4.1 GDS715.0.11.18 -0.5579 266 183 444 1.10044677262163e-37 8.3753966070921e-37 infection control adenovirus adenovirus carrying estrogen receptor beta agent none scopolamine methyl bromide GDS2617.0.1 GDS715.0.8.16 -0.5574 119 109 228 5.18344222251917e-20 2.1996133370637e-19 disease state normal non-tumorigenic cancer cell agent none 1,10-phenanthroline GDS1574.8.9.10 GDS2635.0.3 0.5570 360 300 654 1.44888174551479e-54 1.68185944570818e-53 agent control endotoxin disease state lobular control invasive ductal carcinoma GDS1259.0.1 GDS1956.0.10 0.5555 2867 2334 4346 0 0 disease state normal dermatomyositis disease state normal dysferlin mutation GDS2635.0.2 GDS715.0.11.18 -0.5544 263 183 444 3.84808159772566e-37 2.88186449937356e-36 disease state lobular control invasive lobular carcinoma agent none scopolamine methyl bromide GDS1543.0.1 GDS2414.0.1.4 0.5538 466 129 582 4.39716893883174e-48 4.38175236817496e-47 agent control tumor necrosis factor agent control trophoblast conditioned medium GDS2057.0.1.3 GDS715.0.7.18 0.5538 133 136 267 7.33621621309438e-23 3.47980476108589e-22 agent control DHT agent none 4,5-dianilinophthalimide GDS1259.0.1 GDS1956.0.9 0.5533 2867 2401 4320 0 0 disease state normal dermatomyositis disease state normal Calpain 3 mutation GDS1841.0.1 GDS1841.0.2 0.5518 1495 1669 2510 5.17353070601478e-200 4.53621667365212e-198 agent empty vector wild-type surfactant protein C agent empty vector misfolded surfactant protein C GDS2216.0.1.5 GDS2635.0.3 -0.5516 244 300 541 2.14551624242299e-44 1.95398944356401e-43 agent control LPS disease state lobular control invasive ductal carcinoma GDS2635.0.3 GDS715.0.8.16 -0.5514 300 109 408 7.90496295574775e-34 5.39189999450928e-33 disease state lobular control invasive ductal carcinoma agent none 1,10-phenanthroline GDS2635.0.3 GDS715.0.3.18 -0.5510 300 592 876 1.04180231462969e-70 1.70788453181511e-69 disease state lobular control invasive ductal carcinoma agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1392.0.1 GDS715.0.3.18 -0.5507 413 592 977 1.44276693759751e-78 2.74044350349533e-77 disease state normal rheumatoid arthritis, on methotrexate agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2250.0.3 GDS2418.0.1 0.5505 232 2548 2622 1.11053400367253e-207 1.03004226195489e-205 disease state normal basal-like cancer disease state control vulvar intraepithelial neoplasia GDS2216.0.1.5 GDS266.0.1.2 0.5501 244 407 644 3.24880754325103e-52 3.56277296496398e-51 agent control LPS disease state no atopy atopy GDS2617.0.1 GDS715.2.6.18 -0.5495 119 582 694 5.30901070278405e-56 6.38010670143053e-55 disease state normal non-tumorigenic cancer cell agent negative control 16-ketoestradiol GDS2142.0.1 GDS715.2.3.18 -0.5487 226 266 486 1.48116900261666e-39 1.1881476006443e-38 disease state normal mild cystic fibrosis agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1956.0.5 GDS1956.0.8 0.5477 2945 3999 5673 0 0 disease state normal fascioscapulohumeral muscular dystrophy disease state normal Duchenne muscular dystrophy GDS1543.0.1 GDS2216.0.1.5 0.5467 466 244 699 9.98659047981427e-56 1.19185970445842e-54 agent control tumor necrosis factor agent control LPS GDS2341.0.1.4 GDS2414.0.1.4 0.5458 217 129 338 1.24082027125912e-27 6.98245563414282e-27 agent untreated Type I IFN agent control trophoblast conditioned medium GDS1574.8.9.13 GDS2164.0.1 -0.5429 1931 1302 3045 4.87749639373865e-233 5.56693663945878e-231 agent control endotoxin agent control SIV-Nef GDS2142.0.1 GDS2216.0.1.5 -0.5417 226 244 468 4.82431587770665e-37 3.602287293103e-36 disease state normal mild cystic fibrosis agent control LPS GDS2367.0.1.3 GDS715.0.6.18 0.5407 187 1378 1542 8.54398181683986e-118 3.02901732351066e-116 agent vehicle estradiol agent none 16-ketoestradiol GDS1926.0.2.4 GDS715.0.7.18 0.5405 119 136 254 1.14107310661144e-20 4.97745045686143e-20 agent control LTD4 agent none 4,5-dianilinophthalimide GDS1574.8.9.10 GDS2057.0.1.3 -0.5401 360 133 493 1.11871066333438e-38 8.76837516524274e-38 agent control endotoxin agent control DHT GDS2617.0.1 GDS715.0.3.18 -0.5396 119 592 704 1.9307459402712e-54 2.23514015288304e-53 disease state normal non-tumorigenic cancer cell agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2142.0.1 GDS715.0.14.18 -0.5371 226 141 365 1.15107603783129e-28 6.71602572800297e-28 disease state normal mild cystic fibrosis agent none R-(-)-apomorphine HCl GDS2142.0.1 GDS2367.3.4.1 -0.5369 226 266 486 1.22674768161091e-37 9.32465620647767e-37 disease state normal mild cystic fibrosis infection control adenovirus adenovirus carrying estrogen receptor beta GDS266.0.1.2 GDS715.0.6.18 0.5366 407 1378 1747 7.44176112507374e-131 3.11357389806892e-129 disease state no atopy atopy agent none 16-ketoestradiol GDS2617.0.2 GDS2635.0.2 0.5364 503 263 748 5.91714760806372e-57 7.27503846256695e-56 disease state normal tumorigenic cancer cell disease state lobular control invasive lobular carcinoma GDS715.0.1.18 GDS715.0.14.18 0.5363 3116 141 3157 1.19568032198665e-234 1.37693977600178e-232 agent none positive control agent none R-(-)-apomorphine HCl GDS1353.0.1.2 GDS715.2.6.18 0.5345 1304 582 1804 7.89335635887578e-134 3.42345503648082e-132 agent control dexamethasone agent negative control 16-ketoestradiol GDS2142.0.1 GDS715.0.3.18 -0.5309 226 592 810 4.2803880640156e-60 5.64250006372037e-59 disease state normal mild cystic fibrosis agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.0.11.18 GDS715.0.7.18 -0.5308 183 136 311 5.28324678084386e-24 2.61543451778909e-23 agent none scopolamine methyl bromide agent none 4,5-dianilinophthalimide GDS2057.0.1.3 GDS715.2.3.18 0.5306 133 266 396 3.87381034942909e-30 2.36693493467878e-29 agent control DHT agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1353.0.1.2 GDS715.0.3.18 0.5294 1304 592 1819 6.15866121600961e-132 2.60362027067318e-130 agent control dexamethasone agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2057.0.2.3 GDS715.0.7.18 0.5281 117 136 252 1.6814757528833e-19 6.98580510498754e-19 agent control RTI-018 agent none 4,5-dianilinophthalimide GDS1956.0.6 GDS1956.0.7 0.5264 2160 1627 3230 9.57141499281724e-230 1.06634902112875e-227 disease state normal Emery-Dreifuss muscular dystrophy disease state normal Becker muscular dystrophy GDS2250.0.3 GDS2617.0.2 0.5264 232 503 681 8.32834253922137e-50 8.62282707244478e-49 disease state normal basal-like cancer disease state normal tumorigenic cancer cell GDS2635.0.2 GDS715.0.14.18 -0.5262 263 141 398 1.00403963913094e-29 6.05832428817488e-29 disease state lobular control invasive lobular carcinoma agent none R-(-)-apomorphine HCl GDS1392.0.1 GDS715.2.3.18 -0.5257 413 266 666 1.34789911979291e-48 1.35909440226956e-47 disease state normal rheumatoid arthritis, on methotrexate agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1326.2.3.1 GDS2216.0.1.5 0.5245 181 244 424 2.42811903862144e-31 1.53899770735145e-30 agent control E2 agent control LPS GDS1326.2.3.1 GDS715.0.3.18 0.5245 181 592 765 2.72486268535829e-55 3.22204464565109e-54 agent control E2 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2057.0.1.3 GDS715.0.3.18 0.5232 133 592 717 1.24504783253722e-51 1.34505949314916e-50 agent control DHT agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.0.13.18 GDS715.2.12.18 0.5232 274 117 374 1.14290914703102e-27 6.43924768624169e-27 agent none 8-(3-chlorostyryl) caffeine agent negative control 5-fluorouracil GDS715.1.2.18 GDS715.2.3.18 0.5224 2226 266 2369 4.91734709051493e-166 3.10420457598984e-164 agent negative control positive control agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2617.0.1 GDS715.0.11.18 -0.5213 119 183 301 2.25669963487112e-22 1.05138033023203e-21 disease state normal non-tumorigenic cancer cell agent none scopolamine methyl bromide GDS1956.0.10 GDS1956.0.6 0.5201 2334 2160 3775 9.7698759076774e-261 1.28130411738671e-258 disease state normal dysferlin mutation disease state normal Emery-Dreifuss muscular dystrophy GDS2341.0.1.4 GDS715.0.3.18 0.5194 217 592 796 3.36445232674987e-56 4.05970966468569e-55 agent untreated Type I IFN agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1062.2.3.0 GDS2367.0.2.3 -0.5188 483 282 759 1.59929300716071e-53 1.81045806052482e-52 disease state no metastasis metastasis agent vehicle tamoxifen GDS1326.2.3.1 GDS715.2.3.18 0.5186 181 266 441 9.99774619697591e-32 6.41202912215667e-31 agent control E2 agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2142.0.1 GDS715.0.7.18 -0.5185 226 136 356 6.90380352884662e-26 3.66111037485499e-25 disease state normal mild cystic fibrosis agent none 4,5-dianilinophthalimide GDS2216.0.1.5 GDS2341.0.3.4 0.5134 244 494 724 6.20627832872655e-50 6.44305864567204e-49 agent control LPS agent untreated Types I and II IFNs GDS1392.0.1 GDS2216.0.1.5 -0.5107 413 244 643 5.2937235848243e-44 4.77680090991759e-43 disease state normal rheumatoid arthritis, on methotrexate agent control LPS GDS2142.0.1 GDS715.2.6.18 -0.5104 226 582 797 4.39740955854314e-54 5.0432894317386e-53 disease state normal mild cystic fibrosis agent negative control 16-ketoestradiol GDS715.0.8.16 GDS715.2.6.18 -0.5101 109 582 684 1.39004732807123e-46 1.3362252765949e-45 agent none 1,10-phenanthroline agent negative control 16-ketoestradiol GDS2250.0.1 GDS2617.0.1 0.5090 160 119 259 1.78115445896431e-18 7.06971453617357e-18 disease state normal non-basal-like cancer disease state normal non-tumorigenic cancer cell GDS2341.0.3.4 GDS2414.0.1.4 0.5088 494 129 603 5.07799293607257e-41 4.23904717710465e-40 agent untreated Types I and II IFNs agent control trophoblast conditioned medium GDS1574.8.9.13 GDS2362.6.7.2.5 -0.5083 1931 797 2534 1.4173785335037e-166 9.02155193747168e-165 agent control endotoxin agent untreated chloroguine treated GDS1392.0.1 GDS1574.8.9.11 0.5079 413 567 961 3.74171733818282e-64 5.37061433622193e-63 disease state normal rheumatoid arthritis, on methotrexate agent control endotoxin GDS1353.0.1.2 GDS715.0.7.18 0.5064 1304 136 1434 3.02268741140225e-94 7.56129968281115e-93 agent control dexamethasone agent none 4,5-dianilinophthalimide GDS1574.8.9.10 GDS2057.0.2.3 -0.5058 360 117 477 2.39006414222946e-32 1.55995793112953e-31 agent control endotoxin agent control RTI-018 GDS2164.0.1 GDS715.0.6.18 0.5058 1302 1378 2493 4.61586090386871e-162 2.78704386317346e-160 agent control SIV-Nef agent none 16-ketoestradiol GDS1956.0.2 GDS1956.0.9 0.5041 6836 2401 7588 0 0 disease state normal juvenile dermatomyositis disease state normal Calpain 3 mutation GDS2341.0.2.5 GDS2414.0.1.4 0.5039 579 129 688 1.39890376955145e-45 1.31341431583737e-44 agent untreated Type II IFN agent control trophoblast conditioned medium GDS2617.0.1 GDS715.0.14.18 -0.5039 119 141 258 5.09478338615053e-18 1.98159717612433e-17 disease state normal non-tumorigenic cancer cell agent none R-(-)-apomorphine HCl GDS1956.0.11 GDS1956.0.2 0.5029 2145 6836 7503 0 0 disease state normal FKRP mutation disease state normal juvenile dermatomyositis GDS715.0.1.18 GDS715.0.3.18 0.5021 3116 592 3360 4.1370160509787e-214 4.09100362583283e-212 agent none positive control agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1326.2.3.1 GDS2367.0.1.3 -0.5009 181 187 352 9.34583272062017e-24 4.58925795478847e-23 agent control E2 agent vehicle estradiol GDS2250.0.1 GDS2418.0.1 0.5008 160 2548 2603 2.55907234033938e-165 1.60234232733642e-163 disease state normal non-basal-like cancer disease state control vulvar intraepithelial neoplasia GDS1331.0.1 GDS1353.0.1.2 0.4995 1070 1304 2236 1.97150815251701e-141 9.39200891793208e-140 disease state normal presymptomatic agent control dexamethasone GDS1574.8.9.13 GDS715.1.2.18 0.4995 1931 2226 3870 2.17402109432403e-243 2.61508045685629e-241 agent control endotoxin agent negative control positive control GDS1574.8.9.10 GDS266.0.1.2 -0.4982 360 407 754 1.50773362701348e-48 1.51747391891667e-47 agent control endotoxin disease state no atopy atopy GDS2057.0.1.3 GDS715.0.8.16 0.4979 133 109 241 1.67674469163301e-16 6.06691664056613e-16 agent control DHT agent none 1,10-phenanthroline GDS2635.0.2 GDS715.0.6.18 -0.4973 263 1378 1613 1.64609937804926e-101 4.58727778178998e-100 disease state lobular control invasive lobular carcinoma agent none 16-ketoestradiol GDS715.0.13.18 GDS715.2.5.18 -0.4969 274 3040 3216 3.50753741055746e-200 3.08776168160683e-198 agent none 8-(3-chlorostyryl) caffeine agent negative control sulmazole GDS2164.0.1 GDS715.2.6.18 0.4958 1302 582 1811 5.68196358845508e-113 1.88097653539791e-111 agent control SIV-Nef agent negative control 16-ketoestradiol GDS1353.0.1.2 GDS2142.0.2 0.4954 1304 604 1877 8.27562098231872e-117 2.90445216837916e-115 agent control dexamethasone disease state normal severe cystic fibrosis GDS2341.0.3.5 GDS2611.0.3.9 0.4952 741 284 954 3.61415602159642e-60 4.77161209703525e-59 agent untreated Types I and II IFNs agent untreated IFN-gamma GDS1331.0.1 GDS715.2.5.18 -0.4949 1070 3040 3778 1.15536667175085e-232 1.31575313964878e-230 disease state normal presymptomatic agent negative control sulmazole GDS715.0.10.18 GDS715.2.4.18 -0.4936 158 3836 3915 1.39083099702834e-239 1.63593478011605e-237 agent none pergolide methanesulfonate agent negative control a-methyl-L-p-tyrosine GDS1326.2.3.1 GDS715.2.6.18 0.4930 181 582 755 1.72898943857008e-47 1.69949909262562e-46 agent control E2 agent negative control 16-ketoestradiol GDS1956.0.3 GDS2153.0.1 0.4924 4453 1932 5416 0 0 disease state normal amyotophic lateral sclerosis disease state normal dermatomyositis GDS1574.8.9.11 GDS2142.0.1 0.4910 567 226 778 1.90490409447406e-48 1.912709114819e-47 agent control endotoxin disease state normal mild cystic fibrosis GDS2216.0.1.5 GDS2221.0.3 0.4909 244 970 1175 2.770890090063e-72 4.67231621788514e-71 agent control LPS agent untreated lipopolysaccharide GDS715.0.11.18 GDS715.2.12.18 0.4900 183 117 286 1.11541609792807e-18 4.47236206151219e-18 agent none scopolamine methyl bromide agent negative control 5-fluorouracil GDS1574.8.9.11 GDS2414.0.1.4 0.4899 567 129 684 1.41200622526529e-42 1.22813341025803e-41 agent control endotoxin agent control trophoblast conditioned medium GDS2341.0.1.5 GDS2635.0.2 0.4899 136 263 398 2.04260835798697e-25 1.06580217193718e-24 agent untreated Type I IFN disease state lobular control invasive lobular carcinoma GDS2341.0.2.5 GDS2611.0.3.9 0.4895 579 284 802 1.49041223706296e-49 1.53167945146907e-48 agent untreated Type II IFN agent untreated IFN-gamma GDS1392.0.1 GDS715.2.6.18 -0.4894 413 582 964 3.34569050593868e-59 4.32555401669731e-58 disease state normal rheumatoid arthritis, on methotrexate agent negative control 16-ketoestradiol GDS2142.0.1 GDS715.0.8.16 -0.4889 226 109 331 2.72462836115304e-21 1.21751321921964e-20 disease state normal mild cystic fibrosis agent none 1,10-phenanthroline GDS1926.0.3.4 GDS715.0.7.18 0.4888 135 136 268 1.67787704520583e-17 6.37073932438478e-17 agent control LTD4 and thrombin agent none 4,5-dianilinophthalimide GDS1574.8.9.13 GDS715.0.1.18 0.4880 1931 3116 4604 3.72603565801225e-274 5.27289814753435e-272 agent control endotoxin agent none positive control GDS266.0.1.2 GDS715.0.11.18 0.4877 407 183 585 2.77330496608902e-36 2.03014790174597e-35 disease state no atopy atopy agent none scopolamine methyl bromide GDS2341.0.1.5 GDS715.0.7.18 0.4873 136 136 271 1.4390825914455e-17 5.48176838042067e-17 agent untreated Type I IFN agent none 4,5-dianilinophthalimide GDS715.0.14.18 GDS715.1.2.18 0.4862 141 2226 2288 4.53826057386691e-136 2.02359743822189e-134 agent none R-(-)-apomorphine HCl agent negative control positive control GDS1574.8.9.13 GDS2221.1.3 0.4861 1931 940 2656 1.40075831817459e-157 8.05348600912238e-156 agent control endotoxin agent vehicle lipopolysaccharide GDS2057.0.1.3 GDS2367.3.4.1 0.4861 133 266 397 6.1828392487958e-25 3.17098415379619e-24 agent control DHT infection control adenovirus adenovirus carrying estrogen receptor beta GDS1259.0.1 GDS715.0.6.18 0.4856 2867 1378 3893 1.55377460018571e-229 1.7285549839191e-227 disease state normal dermatomyositis agent none 16-ketoestradiol GDS266.0.1.2 GDS715.0.7.18 0.4852 407 136 534 6.93269702343739e-33 4.59182426237767e-32 disease state no atopy atopy agent none 4,5-dianilinophthalimide GDS1062.2.3.0 GDS2367.0.1.3 -0.4840 483 187 664 2.72936581316942e-40 2.23387078553283e-39 disease state no metastasis metastasis agent vehicle estradiol GDS1331.0.2 GDS2191.0.1 -0.4816 3398 942 3959 4.74342267953116e-229 5.26558509648637e-227 disease state normal symptomatic disease state control bipolar disorder GDS1392.0.1 GDS715.0.14.18 -0.4816 413 141 550 2.78985776854671e-33 1.8714312498288e-32 disease state normal rheumatoid arthritis, on methotrexate agent none R-(-)-apomorphine HCl GDS1062.2.3.0 GDS2216.0.1.5 0.4812 483 244 727 2.10034631418356e-43 1.86529802713545e-42 disease state no metastasis metastasis agent control LPS GDS1062.2.3.0 GDS715.2.4.18 0.4794 483 3836 4255 1.73656344090298e-243 2.09377990614943e-241 disease state no metastasis metastasis agent negative control a-methyl-L-p-tyrosine GDS1926.0.3.4 GDS715.2.3.18 0.4777 135 266 396 5.75265675574182e-24 2.84415481443198e-23 agent control LTD4 and thrombin agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.0.3.18 GDS715.0.9.18 0.4772 592 3151 3597 5.25163428032224e-204 4.75638306615871e-202 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent none 5-fluorouridine GDS2216.0.1.5 GDS2221.0.2 0.4771 244 1338 1531 7.49924302212247e-88 1.68561399061441e-86 agent control LPS agent untreated galectin-1 GDS2057.0.2.3 GDS715.0.3.18 0.4770 117 592 703 3.16986404502304e-41 2.66276681369456e-40 agent control RTI-018 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.0.13.18 GDS715.2.4.18 -0.4766 274 3836 3999 6.07495365177554e-226 6.56386100006909e-224 agent none 8-(3-chlorostyryl) caffeine agent negative control a-methyl-L-p-tyrosine GDS2142.0.1 GDS2635.0.3 -0.4764 226 300 519 9.22269339719109e-31 5.73831035858075e-30 disease state normal mild cystic fibrosis disease state lobular control invasive ductal carcinoma GDS1574.8.9.13 GDS2200.0.1 0.4762 1931 649 2485 7.3072275596116e-141 3.44482943110901e-139 agent control endotoxin disease state normal actinic keratosis GDS1926.0.2.4 GDS715.0.3.18 0.4758 119 592 702 6.07163110071041e-41 5.05728225600219e-40 agent control LTD4 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1326.2.3.1 GDS1574.8.9.10 -0.4756 181 360 534 1.71685174349496e-31 1.09317529374186e-30 agent control E2 agent control endotoxin GDS715.0.10.18 GDS715.0.9.18 0.4750 158 3151 3216 1.03753964460268e-180 7.67651125595371e-179 agent none pergolide methanesulfonate agent none 5-fluorouridine GDS2057.0.2.3 GDS715.2.3.18 0.4749 117 266 380 9.00187159452451e-23 4.25558883350936e-22 agent control RTI-018 agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1050.0.1.2 GDS1050.2.3.0 0.4744 763 1874 2397 8.65193911900293e-135 3.79847226752159e-133 disease state normal polycystic ovary syndrome agent untreated valproic acid GDS2367.0.2.3 GDS2367.3.4.2 -0.4744 282 691 767 2.67873036959687e-44 2.43427680924235e-43 agent vehicle tamoxifen infection control adenovirus adenovirus carrying estrogen receptor beta GDS2057.0.1.3 GDS2216.0.1.5 0.4741 133 244 374 2.34742323151127e-22 1.09258986722596e-21 agent control DHT agent control LPS GDS2216.0.1.5 GDS2221.1.3 0.4739 244 940 1145 3.67995577892792e-65 5.39924221952221e-64 agent control LPS agent vehicle lipopolysaccharide GDS1926.0.2.4 GDS715.0.14.18 0.4737 119 141 259 6.83104688674286e-16 2.40030254886294e-15 agent control LTD4 agent none R-(-)-apomorphine HCl GDS2142.0.1 GDS2414.0.1.4 -0.4736 226 129 348 7.40939249953763e-21 3.25583336494247e-20 disease state normal mild cystic fibrosis agent control trophoblast conditioned medium GDS2216.0.1.5 GDS715.0.6.18 -0.4734 244 1378 1589 1.52377246880762e-89 3.53225885385651e-88 agent control LPS agent none 16-ketoestradiol GDS2341.0.1.5 GDS2367.3.4.1 0.4725 136 266 401 1.08020021755219e-23 5.29299772361814e-23 agent untreated Type I IFN infection control adenovirus adenovirus carrying estrogen receptor beta GDS1956.0.2 GDS1956.0.7 0.4717 6836 1627 7340 0 0 disease state normal juvenile dermatomyositis disease state normal Becker muscular dystrophy GDS2057.0.1.3 GDS715.2.6.18 0.4716 133 582 711 1.18187745986708e-40 9.78079253152105e-40 agent control DHT agent negative control 16-ketoestradiol GDS2164.0.1 GDS2367.3.4.2 0.4716 1302 691 1873 2.45759644904193e-104 7.15702495527436e-103 agent control SIV-Nef infection control adenovirus adenovirus carrying estrogen receptor beta GDS715.0.10.18 GDS715.2.5.18 -0.4716 158 3040 3124 8.819020857643e-173 5.9949205867486e-171 agent none pergolide methanesulfonate agent negative control sulmazole GDS2341.0.1.4 GDS2635.0.3 0.4713 217 300 510 1.45828608617546e-29 8.76316474426744e-29 agent untreated Type I IFN disease state lobular control invasive ductal carcinoma GDS1574.8.9.12 GDS1971.0.2 0.4704 2152 953 2881 1.39891412119016e-158 8.13400330355833e-157 agent control endotoxin disease state healthy complicated malaria GDS2250.0.3 GDS2635.0.3 0.4702 232 300 496 1.19445577154414e-28 6.96411337929619e-28 disease state normal basal-like cancer disease state lobular control invasive ductal carcinoma GDS1331.0.2 GDS1956.0.4 -0.4675 3398 1090 4009 7.09449186296047e-217 7.13472724966294e-215 disease state normal symptomatic disease state normal spastic paraplegia GDS715.0.6.18 GDS715.0.9.18 0.4673 1378 3151 4134 2.31845047697989e-223 2.4567642310003e-221 agent none 16-ketoestradiol agent none 5-fluorouridine GDS1392.0.1 GDS715.0.11.18 -0.4672 413 183 587 3.66624893261651e-33 2.44960101936923e-32 disease state normal rheumatoid arthritis, on methotrexate agent none scopolamine methyl bromide GDS2216.0.1.5 GDS2221.1.2 0.4672 244 1258 1453 1.15028120033989e-79 2.22944137929533e-78 agent control LPS agent vehicle galectin-1 GDS1353.0.1.2 GDS2635.0.2 0.4671 1304 263 1538 3.493282812189e-84 7.34975077965612e-83 agent control dexamethasone disease state lobular control invasive lobular carcinoma GDS2635.0.2 GDS266.0.1.2 0.4670 263 407 658 5.98787297640769e-37 4.45798019118037e-36 disease state lobular control invasive lobular carcinoma disease state no atopy atopy GDS2341.0.1.5 GDS2611.0.3.9 0.4668 136 284 389 1.90882298345388e-22 8.91897912964091e-22 agent untreated Type I IFN agent untreated IFN-gamma GDS1353.0.1.2 GDS715.0.11.18 0.4666 1304 183 1477 1.00910389866745e-80 1.99499224723589e-79 agent control dexamethasone agent none scopolamine methyl bromide GDS2414.0.1.4 GDS2617.0.1 -0.4666 129 119 241 1.96866146467723e-14 6.41505668961294e-14 agent control trophoblast conditioned medium disease state normal non-tumorigenic cancer cell GDS1259.0.1 GDS2200.0.1 0.4665 2867 649 3372 7.50873722591897e-182 5.5931658918366e-180 disease state normal dermatomyositis disease state normal actinic keratosis GDS1353.0.1.2 GDS715.0.14.18 0.4657 1304 141 1436 3.39387716709857e-78 6.40536216481567e-77 agent control dexamethasone agent none R-(-)-apomorphine HCl GDS1926.0.3.4 GDS715.2.6.18 0.4635 135 582 710 4.21911273420135e-39 3.34574345913447e-38 agent control LTD4 and thrombin agent negative control 16-ketoestradiol GDS1353.0.1.2 GDS266.0.1.2 -0.4624 1304 407 1672 2.44506377698383e-89 5.65088975334267e-88 agent control dexamethasone disease state no atopy atopy GDS2635.0.3 GDS715.0.11.18 -0.4620 300 183 477 1.35276136551128e-26 7.35226611807337e-26 disease state lobular control invasive ductal carcinoma agent none scopolamine methyl bromide GDS1926.0.2.4 GDS715.2.3.18 0.4618 119 266 381 1.5990771867504e-21 7.21274853709198e-21 agent control LTD4 agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1956.0.1 GDS1956.0.9 0.4617 4393 2401 5811 8.83740701373436e-305 1.5051774312074e-302 disease state normal acute quadriplegic myopathy disease state normal Calpain 3 mutation GDS2142.0.2 GDS2367.3.4.1 -0.4616 604 266 865 7.29542002836594e-47 7.06543783412686e-46 disease state normal severe cystic fibrosis infection control adenovirus adenovirus carrying estrogen receptor beta GDS1331.0.1 GDS715.2.4.18 -0.4614 1070 3836 4514 7.34985506206324e-237 8.5600951257754e-235 disease state normal presymptomatic agent negative control a-methyl-L-p-tyrosine GDS2164.0.1 GDS2367.0.2.3 -0.4614 1302 282 1538 6.29195418591579e-82 1.27117358942233e-80 agent control SIV-Nef agent vehicle tamoxifen GDS2341.0.1.5 GDS715.2.3.18 0.4613 136 266 400 1.79887013456631e-22 8.41416133775456e-22 agent untreated Type I IFN agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2142.0.2 GDS715.2.3.18 -0.4605 604 266 857 3.32276239871812e-46 3.16584174821572e-45 disease state normal severe cystic fibrosis agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.0.12.18 GDS715.2.9.18 0.4596 131 3560 3638 1.29541880841266e-189 1.03612161927521e-187 agent none 5-fluorouracil agent negative control 5-fluorouridine GDS715.0.14.18 GDS715.0.9.18 0.4593 141 3151 3255 1.31180441455345e-169 8.62777767532486e-168 agent none R-(-)-apomorphine HCl agent none 5-fluorouridine GDS1392.0.1 GDS2142.0.1 -0.4592 413 226 631 3.10491324084546e-34 2.14135796363915e-33 disease state normal rheumatoid arthritis, on methotrexate disease state normal mild cystic fibrosis GDS2057.0.1.3 GDS715.0.14.18 0.4591 133 141 274 1.08662636913112e-15 3.78203761571585e-15 agent control DHT agent none R-(-)-apomorphine HCl GDS715.0.3.18 GDS715.0.8.16 -0.4589 592 109 691 2.75127122243779e-37 2.06951248454709e-36 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent none 1,10-phenanthroline GDS2216.0.1.5 GDS2341.0.2.4 0.4588 244 300 538 2.30836380595552e-29 1.37757680360411e-28 agent control LPS agent untreated Type II IFN GDS1926.0.3.4 GDS715.0.3.18 0.4585 135 592 719 1.16400255332632e-38 9.12104821376679e-38 agent control LTD4 and thrombin agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1353.0.1.2 GDS2367.0.2.3 -0.4582 1304 282 1510 3.04250969296163e-79 5.85269862774456e-78 agent control dexamethasone agent vehicle tamoxifen GDS2142.0.2 GDS2164.0.1 0.4582 604 1302 1860 3.37241729814121e-97 8.84725347070271e-96 disease state normal severe cystic fibrosis agent control SIV-Nef GDS1956.0.10 GDS1956.0.2 0.4575 2334 6836 7626 0 0 disease state normal dysferlin mutation disease state normal juvenile dermatomyositis GDS1326.2.3.1 GDS2367.0.2.3 -0.4573 181 282 443 2.80949872513001e-24 1.40532698471569e-23 agent control E2 agent vehicle tamoxifen GDS2057.0.2.3 GDS715.0.8.16 0.4571 117 109 226 4.5577926337537e-13 1.37448196719797e-12 agent control RTI-018 agent none 1,10-phenanthroline GDS1615.0.2 GDS1971.0.1 0.4570 3399 1356 4121 7.93230146027244e-212 7.64282132918975e-210 disease state normal Crohn's disease disease state healthy uncomplicated malaria GDS2142.0.2 GDS2200.0.1 -0.4568 604 649 1213 1.43218670779084e-63 2.03180070542532e-62 disease state normal severe cystic fibrosis disease state normal actinic keratosis GDS266.0.1.2 GDS715.2.5.18 0.4563 407 3040 3373 3.85258622426038e-173 2.63399685633356e-171 disease state no atopy atopy agent negative control sulmazole GDS2635.0.3 GDS715.0.6.18 -0.4555 300 1378 1641 7.47933161427745e-85 1.5925596159064e-83 disease state lobular control invasive ductal carcinoma agent none 16-ketoestradiol GDS1062.2.3.0 GDS2164.0.1 -0.4551 483 1302 1763 7.48254823511279e-91 1.77597520557113e-89 disease state no metastasis metastasis agent control SIV-Nef GDS1062.2.3.0 GDS715.0.3.18 0.4544 483 592 1055 7.06355506978376e-55 8.26478803061305e-54 disease state no metastasis metastasis agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2021.0.2 GDS2367.3.4.1 0.4541 314 266 573 1.69771093738839e-30 1.04838423253723e-29 agent control nebivolol infection control adenovirus adenovirus carrying estrogen receptor beta GDS715.0.14.18 GDS715.0.8.16 -0.4537 141 109 239 1.54685174029552e-13 4.8001876191733e-13 agent none R-(-)-apomorphine HCl agent none 1,10-phenanthroline GDS266.0.1.2 GDS715.2.4.18 0.4536 407 3836 4162 2.2026765219415e-210 2.09347114512983e-208 disease state no atopy atopy agent negative control a-methyl-L-p-tyrosine GDS1259.0.1 GDS715.0.3.18 0.4533 2867 592 3305 3.22025577755883e-167 2.06246779490983e-165 disease state normal dermatomyositis agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.0.6.18 GDS715.2.4.18 -0.4528 1378 3836 4718 2.74596271200831e-237 3.20539172265034e-235 agent none 16-ketoestradiol agent negative control a-methyl-L-p-tyrosine GDS1926.0.3.4 GDS2216.0.1.5 0.4525 135 244 372 3.54857417038575e-20 1.51730922165974e-19 agent control LTD4 and thrombin agent control LPS GDS1326.2.3.1 GDS715.0.7.18 0.4512 181 136 316 2.96985542371995e-17 1.11399991464418e-16 agent control E2 agent none 4,5-dianilinophthalimide GDS2142.0.1 GDS266.0.1.2 0.4511 226 407 617 2.92712579502205e-32 1.90427404121243e-31 disease state normal mild cystic fibrosis disease state no atopy atopy GDS1926.0.2.4 GDS715.2.6.18 0.4507 119 582 694 5.07453176581414e-36 3.68650066480109e-35 agent control LTD4 agent negative control 16-ketoestradiol GDS1956.0.1 GDS715.2.4.18 -0.4503 4393 3836 7016 0 0 disease state normal acute quadriplegic myopathy agent negative control a-methyl-L-p-tyrosine GDS1926.0.3.4 GDS2367.3.4.1 0.4502 135 266 395 4.14621678947273e-21 1.84020606631325e-20 agent control LTD4 and thrombin infection control adenovirus adenovirus carrying estrogen receptor beta GDS1392.0.1 GDS2118.0.2 0.4479 413 2118 2426 4.99334489084774e-120 1.82790477182847e-118 disease state normal rheumatoid arthritis, on methotrexate disease state normal refractory anemia with ringed sideroblasts GDS2635.0.3 GDS715.0.14.18 -0.4470 300 141 436 8.35142134044428e-23 3.9528251379561e-22 disease state lobular control invasive ductal carcinoma agent none R-(-)-apomorphine HCl GDS2367.3.4.1 GDS2428.0.1.3 0.4469 266 181 441 4.87581143356445e-23 2.32897041085632e-22 infection control adenovirus adenovirus carrying estrogen receptor beta agent untreated 5-aza-dC GDS1392.0.1 GDS266.0.1.2 0.4469 413 407 789 5.3360749940937e-40 4.33509029702881e-39 disease state normal rheumatoid arthritis, on methotrexate disease state no atopy atopy GDS1220.0.1.3 GDS2142.0.2 0.4458 1705 604 2228 3.0164348927636e-109 9.46475047703468e-108 disease state normal malignant pleural mesothelioma disease state normal severe cystic fibrosis GDS1062.2.3.0 GDS715.2.3.18 0.4453 483 266 739 2.79910989989655e-37 2.10508547631324e-36 disease state no metastasis metastasis agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1574.8.9.13 GDS2221.0.3 0.4451 1931 970 2679 1.56211758236742e-130 6.50748280381458e-129 agent control endotoxin agent untreated lipopolysaccharide GDS2213.0.2 GDS2213.0.3 0.4447 385 1316 1565 7.41879764350499e-77 1.36820214515391e-75 agent untreated TSA agent untreated 5-aza-dC plus TSA GDS715.0.11.18 GDS715.0.3.18 -0.4441 183 592 752 1.08941246379367e-37 8.29344713088855e-37 agent none scopolamine methyl bromide agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2142.0.2 GDS715.0.3.18 -0.4439 604 592 1165 1.98384317328684e-57 2.46429149024151e-56 disease state normal severe cystic fibrosis agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1574.8.9.13 GDS1617.0.5 0.4438 1931 1981 3581 1.0140021635242e-172 6.88985761924168e-171 agent control endotoxin agent control MGd/50uM zinc GDS715.0.6.18 GDS715.2.5.18 -0.4436 1378 3040 3955 2.29298451856112e-190 1.84841305147684e-188 agent none 16-ketoestradiol agent negative control sulmazole GDS1926.0.3.4 GDS715.0.14.18 0.4433 135 141 276 1.02735617436265e-14 3.39924072275607e-14 agent control LTD4 and thrombin agent none R-(-)-apomorphine HCl GDS1926.0.2.4 GDS2216.0.1.5 0.4423 119 244 360 1.12413870294359e-18 4.50674932152457e-18 agent control LTD4 agent control LPS GDS2142.0.1 GDS715.0.11.18 -0.4416 226 183 399 1.78735423163515e-20 7.7363056599422e-20 disease state normal mild cystic fibrosis agent none scopolamine methyl bromide GDS2216.0.1.5 GDS2255.3.4.0 0.4416 244 321 543 2.52996763926071e-27 1.40855099401368e-26 agent control LPS agent untreated endotoxin GDS715.0.14.18 GDS715.0.15.18 0.4410 141 452 551 1.26507382730379e-27 7.11711659691305e-27 agent none R-(-)-apomorphine HCl agent none cyclazosin HCl GDS1326.2.3.1 GDS715.0.8.16 0.4403 181 109 287 4.8695105461531e-15 1.63883404098348e-14 agent control E2 agent none 1,10-phenanthroline GDS2341.0.1.4 GDS2367.0.2.3 -0.4376 217 282 493 1.76899449816193e-24 8.91756043177557e-24 agent untreated Type I IFN agent vehicle tamoxifen GDS715.0.11.18 GDS715.0.12.18 0.4374 183 131 292 4.47848196706638e-15 1.51010508929942e-14 agent none scopolamine methyl bromide agent none 5-fluorouracil GDS2057.0.2.3 GDS715.2.6.18 0.4373 117 582 692 1.09234853581966e-33 7.42154400297371e-33 agent control RTI-018 agent negative control 16-ketoestradiol GDS1331.0.1 GDS1956.0.4 -0.4371 1070 1090 2031 1.54816235315037e-95 3.95106749089804e-94 disease state normal presymptomatic disease state normal spastic paraplegia GDS1439.0.1 GDS1439.0.2 0.4369 1549 3178 3995 6.40506546883703e-186 4.95815456356891e-184 disease state benign primary disease state benign metastatic GDS1956.0.3 GDS1956.0.8 0.4359 4453 3999 6608 1.15532161459245e-304 1.96555676361469e-302 disease state normal amyotophic lateral sclerosis disease state normal Duchenne muscular dystrophy GDS2164.0.1 GDS266.0.1.2 -0.4358 1302 407 1690 2.78372945353299e-79 5.36092618665833e-78 agent control SIV-Nef disease state no atopy atopy GDS715.2.12.18 GDS715.2.9.18 0.4357 117 3560 3610 3.55323070365483e-167 2.27478102314706e-165 agent negative control 5-fluorouracil agent negative control 5-fluorouridine GDS1574.8.9.13 GDS715.2.5.18 0.4356 1931 3040 4321 1.28996919056527e-199 1.12913213984672e-197 agent control endotoxin agent negative control sulmazole GDS1439.0.2 GDS2250.0.1 0.4347 3178 160 3232 4.05766322155708e-149 2.12428237171577e-147 disease state benign metastatic disease state normal non-basal-like cancer GDS2021.0.2 GDS2367.0.1.3 -0.4338 314 187 498 2.87541063511373e-24 1.43768929946489e-23 agent control nebivolol agent vehicle estradiol GDS2057.0.2.3 GDS715.0.14.18 0.4330 117 141 258 3.25116046965656e-13 9.89358052658873e-13 agent control RTI-018 agent none R-(-)-apomorphine HCl GDS651.0.1 GDS715.2.4.18 0.4330 4221 3836 6883 0 0 disease state normal idiopathic dilated agent negative control a-methyl-L-p-tyrosine GDS715.0.7.18 GDS715.2.6.18 -0.4326 136 582 681 1.9809747434662e-32 1.29586303690609e-31 agent none 4,5-dianilinophthalimide agent negative control 16-ketoestradiol GDS1392.0.1 GDS715.0.6.18 -0.4323 413 1378 1727 1.42388296012711e-79 2.75452716141043e-78 disease state normal rheumatoid arthritis, on methotrexate agent none 16-ketoestradiol GDS1397.0.2 GDS715.0.8.16 -0.4322 590 109 696 4.80636466717673e-33 3.19928979614749e-32 agent untreated TNF-alpha agent none 1,10-phenanthroline GDS1574.8.9.11 GDS2021.0.2 -0.4309 567 314 857 4.62751438976481e-40 3.76620389228105e-39 agent control endotoxin agent control nebivolol GDS2118.0.1 GDS2397.0.1 0.4306 934 580 1375 3.58857233337132e-63 5.04313915815684e-62 disease state normal refractory anemia disease state normal idiopathic myelofibrosis GDS2057.0.2.3 GDS2216.0.1.5 0.4292 117 244 359 1.59929770679496e-17 6.0768767899757e-17 agent control RTI-018 agent control LPS GDS1574.8.9.13 GDS715.0.15.18 0.4290 1931 452 2307 6.09576170110095e-104 1.76386764173914e-102 agent control endotoxin agent none cyclazosin HCl GDS1574.8.9.11 GDS1615.0.2 0.4288 567 3399 3744 2.42592878818603e-167 1.55566886283852e-165 agent control endotoxin disease state normal Crohn's disease GDS1956.0.1 GDS1956.0.11 0.4288 4393 2145 5631 1.1005667062381e-250 1.37878248817649e-248 disease state normal acute quadriplegic myopathy disease state normal FKRP mutation GDS1062.2.3.0 GDS715.0.8.16 0.4284 483 109 589 1.08983539731823e-27 6.1442726683075e-27 disease state no metastasis metastasis agent none 1,10-phenanthroline GDS715.0.11.18 GDS715.2.5.18 -0.4281 183 3040 3199 9.44525504129e-143 4.57317520718193e-141 agent none scopolamine methyl bromide agent negative control sulmazole GDS2617.0.1 GDS2737.0.1.3 0.4279 119 739 841 9.15207646603834e-39 7.19273908215163e-38 disease state normal non-tumorigenic cancer cell disease state normal endometriosis GDS715.0.3.18 GDS715.1.2.18 0.4279 592 2226 2576 3.36480188814048e-115 1.15204085964321e-113 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent negative control positive control GDS2142.0.2 GDS715.2.5.18 -0.4270 604 3040 3523 3.91033435303566e-156 2.21755975090261e-154 disease state normal severe cystic fibrosis agent negative control sulmazole GDS1326.2.3.1 GDS715.0.6.18 0.4269 181 1378 1539 3.37638525350883e-69 5.38487927777793e-68 agent control E2 agent none 16-ketoestradiol GDS2341.0.1.4 GDS715.2.6.18 0.4267 217 582 789 2.98160287972732e-36 2.18034804375838e-35 agent untreated Type I IFN agent negative control 16-ketoestradiol GDS2216.0.1.5 GDS2428.0.1.3 0.4266 244 181 422 4.31625916496601e-20 1.83891922665525e-19 agent control LPS agent untreated 5-aza-dC GDS1062.2.3.0 GDS1353.0.1.2 -0.4260 483 1304 1750 4.36058416821639e-78 8.21676250194908e-77 disease state no metastasis metastasis agent control dexamethasone GDS1447.0.1 GDS2617.0.1 -0.4259 242 119 347 1.00843499069193e-16 3.68700146279485e-16 agent control vanadium disease state normal non-tumorigenic cancer cell GDS2142.0.2 GDS2216.0.1.5 -0.4259 604 244 840 2.44163129363123e-38 1.89587867161293e-37 disease state normal severe cystic fibrosis agent control LPS GDS1392.0.1 GDS2118.0.1 0.4257 413 934 1296 3.4222458084806e-58 4.32147393139003e-57 disease state normal rheumatoid arthritis, on methotrexate disease state normal refractory anemia GDS2057.0.2.3 GDS2367.3.4.1 0.4256 117 266 381 3.40423388949024e-18 1.3339035277292e-17 agent control RTI-018 infection control adenovirus adenovirus carrying estrogen receptor beta GDS1392.0.1 GDS2164.0.1 0.4251 413 1302 1672 2.40598350484765e-74 4.22930874422848e-73 disease state normal rheumatoid arthritis, on methotrexate agent control SIV-Nef GDS1397.0.2 GDS715.0.14.18 -0.4242 590 141 725 4.96680079443384e-33 3.30379659584899e-32 agent untreated TNF-alpha agent none R-(-)-apomorphine HCl GDS1746.2.4.0 GDS2635.0.2 -0.4236 222 263 478 3.09411654543472e-22 1.4342359607153e-21 disease state normal basaloid disease state lobular control invasive lobular carcinoma GDS2164.0.1 GDS715.2.5.18 0.4227 1302 3040 3891 1.79742609207325e-168 1.16672264759438e-166 agent control SIV-Nef agent negative control sulmazole GDS2341.0.1.4 GDS715.0.6.18 0.4226 217 1378 1571 4.45513794483618e-69 7.09138785091002e-68 agent untreated Type I IFN agent none 16-ketoestradiol GDS1259.0.1 GDS651.0.1 -0.4225 2867 4221 6086 4.07233113168621e-262 5.40525722829469e-260 disease state normal dermatomyositis disease state normal idiopathic dilated GDS1392.0.1 GDS715.0.7.18 -0.4225 413 136 537 1.1607225286964e-24 5.89272146487533e-24 disease state normal rheumatoid arthritis, on methotrexate agent none 4,5-dianilinophthalimide GDS1543.0.1 GDS2367.3.4.2 0.4218 466 691 1108 5.03434952297775e-49 5.1190738337002e-48 agent control tumor necrosis factor infection control adenovirus adenovirus carrying estrogen receptor beta GDS1257.0.1 GDS1257.0.2 0.4217 232 850 1029 1.2637730432235e-45 1.18857105571376e-44 disease state normal SCD with acute chest syndrome disease state normal SCD steady state GDS1353.0.1.2 GDS2164.0.1 -0.4217 1304 1302 2342 1.24732945466361e-101 3.48230600921884e-100 agent control dexamethasone agent control SIV-Nef GDS1062.2.3.0 GDS2142.0.1 0.4217 483 226 700 1.49098709126414e-31 9.5109054453462e-31 disease state no metastasis metastasis disease state normal mild cystic fibrosis GDS1574.8.9.10 GDS1926.0.2.4 -0.4215 360 119 473 8.5227345340388e-22 3.88360358671864e-21 agent control endotoxin agent control LTD4 GDS1956.0.1 GDS715.2.5.18 -0.4215 4393 3040 6470 4.40418631162237e-277 6.39721708733361e-275 disease state normal acute quadriplegic myopathy agent negative control sulmazole GDS715.0.13.18 GDS715.0.9.18 0.4213 274 3151 3315 8.8053887126146e-143 4.26739249264633e-141 agent none 8-(3-chlorostyryl) caffeine agent none 5-fluorouridine GDS2142.0.2 GDS715.2.4.18 -0.4210 604 3836 4305 1.47695934495188e-184 1.12688254062667e-182 disease state normal severe cystic fibrosis agent negative control a-methyl-L-p-tyrosine GDS1353.0.1.2 GDS2635.0.3 0.4201 1304 300 1564 6.61075997143766e-68 1.0282325208622e-66 agent control dexamethasone disease state lobular control invasive ductal carcinoma GDS1326.2.3.1 GDS715.0.14.18 0.4196 181 141 321 4.03411373136468e-15 1.36361266940628e-14 agent control E2 agent none R-(-)-apomorphine HCl GDS1574.8.9.13 GDS715.2.4.18 0.4195 1931 3836 5001 2.06739116016661e-212 2.00828183238653e-210 agent control endotoxin agent negative control a-methyl-L-p-tyrosine GDS715.2.15.18 GDS715.2.3.18 0.4186 356 266 596 1.09948648356354e-26 5.99645948654856e-26 agent negative control cyclazosin HCl agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2635.0.3 GDS715.0.7.18 -0.4180 300 136 429 1.42748258253459e-19 5.94758468538666e-19 disease state lobular control invasive ductal carcinoma agent none 4,5-dianilinophthalimide GDS2341.0.1.5 GDS2367.0.1.3 -0.4178 136 187 320 5.97694622054971e-15 2.00256812562659e-14 agent untreated Type I IFN agent vehicle estradiol GDS1392.0.2 GDS2118.0.1 0.4172 732 934 1526 2.5416466908206e-65 3.74159079193401e-64 disease state normal myelodysplastic syndrome disease state normal refractory anemia GDS2341.0.1.5 GDS2649.3.5.0 0.4171 136 229 324 4.54370308621227e-15 1.5315939525527e-14 agent untreated Type I IFN disease state uninfected chronic HIV infection GDS1574.8.9.13 GDS2221.1.2 0.4167 1931 1258 2867 7.91840412284665e-121 2.93072860384905e-119 agent control endotoxin agent vehicle galectin-1 GDS1062.2.3.0 GDS715.2.5.18 0.4161 483 3040 3458 6.85504230204282e-145 3.40800485563985e-143 disease state no metastasis metastasis agent negative control sulmazole GDS715.0.14.18 GDS715.2.5.18 -0.4158 141 3040 3156 3.39243760945194e-132 1.44010973031236e-130 agent none R-(-)-apomorphine HCl agent negative control sulmazole GDS266.0.1.2 GDS715.0.4.18 0.4150 407 5001 5302 7.74375286006692e-220 7.9698686087954e-218 disease state no atopy atopy agent none a-methyl-L-p-tyrosine GDS1353.0.1.2 GDS715.2.3.18 0.4148 1304 266 1529 1.21135771487102e-64 1.75671723971108e-63 agent control dexamethasone agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2164.0.1 GDS2213.0.1 -0.4147 1302 1016 2156 2.23227389555784e-90 5.26177866433022e-89 agent control SIV-Nef agent untreated 5-aza-dC GDS1956.0.3 GDS2191.0.1 -0.4137 4453 942 4936 2.09576380238943e-203 1.88812848147795e-201 disease state normal amyotophic lateral sclerosis disease state control bipolar disorder GDS715.0.3.18 GDS715.2.5.18 -0.4134 592 3040 3456 8.9188725602337e-143 4.32103054832051e-141 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent negative control sulmazole GDS2057.0.1.3 GDS2367.0.1.3 -0.4130 133 187 312 2.78211272566178e-14 8.99286469058032e-14 agent control DHT agent vehicle estradiol GDS1392.0.2 GDS2118.0.3 0.4123 732 976 1548 1.38541808693505e-64 2.006872200919e-63 disease state normal myelodysplastic syndrome disease state normal refractory anemia with excess blasts GDS715.0.14.18 GDS715.2.15.18 0.4116 141 356 478 5.72207721120554e-21 2.5263625506716e-20 agent none R-(-)-apomorphine HCl agent negative control cyclazosin HCl GDS2021.0.2 GDS2367.0.2.3 -0.4115 314 282 587 2.15154124087154e-25 1.12138761045495e-24 agent control nebivolol agent vehicle tamoxifen GDS651.0.1 GDS715.0.4.18 0.4115 4221 5001 7648 0 0 disease state normal idiopathic dilated agent none a-methyl-L-p-tyrosine GDS1331.0.1 GDS2191.0.1 -0.4111 1070 942 1909 9.65217909880644e-79 1.84109199461428e-77 disease state normal presymptomatic disease state control bipolar disorder GDS2341.0.1.4 GDS266.0.1.2 -0.4107 217 407 614 2.19483624500415e-26 1.18486438596318e-25 agent untreated Type I IFN disease state no atopy atopy GDS1956.0.1 GDS715.0.4.18 -0.4104 4393 5001 7772 0 0 disease state normal acute quadriplegic myopathy agent none a-methyl-L-p-tyrosine GDS2635.0.3 GDS715.2.5.18 -0.4100 300 3040 3293 1.01588386598268e-133 4.3985910053878e-132 disease state lobular control invasive ductal carcinoma agent negative control sulmazole GDS1574.8.9.11 GDS2617.0.2 -0.4098 567 503 1041 1.99675307003048e-43 1.77493588632772e-42 agent control endotoxin disease state normal tumorigenic cancer cell GDS1956.0.3 GDS715.2.4.18 -0.4081 4453 3836 6745 4.26115697727873e-269 5.89472623546766e-267 disease state normal amyotophic lateral sclerosis agent negative control a-methyl-L-p-tyrosine GDS2216.0.1.5 GDS2649.3.5.0 0.4073 244 229 469 3.61280056096861e-20 1.54421382712955e-19 agent control LPS disease state uninfected chronic HIV infection GDS2428.0.1.3 GDS715.0.3.18 0.4072 181 592 757 1.34073559898309e-31 8.56417027116272e-31 agent untreated 5-aza-dC agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1574.8.9.10 GDS2250.0.1 0.4059 360 160 516 6.91599502748616e-22 3.16193215062824e-21 agent control endotoxin disease state normal non-basal-like cancer GDS2250.0.3 GDS2617.0.1 0.4059 232 119 340 6.44247731636682e-15 2.15516703750059e-14 disease state normal basal-like cancer disease state normal non-tumorigenic cancer cell GDS2164.0.1 GDS2635.0.2 0.4055 1302 263 1539 5.5313489452189e-62 7.58507577810614e-61 agent control SIV-Nef disease state lobular control invasive lobular carcinoma GDS1574.8.9.13 GDS2200.0.2 0.4045 1931 1112 2872 1.6379819561688e-113 5.45645330856685e-112 agent control endotoxin disease state normal squamous cell carcinoma GDS2057.0.1.3 GDS715.0.6.18 0.4045 133 1378 1499 4.21595804513981e-60 5.55851882139443e-59 agent control DHT agent none 16-ketoestradiol GDS1353.0.1.2 GDS1392.0.1 0.4039 1304 413 1655 5.75082618692065e-66 8.57989188729895e-65 agent control dexamethasone disease state normal rheumatoid arthritis, on methotrexate GDS1353.0.1.2 GDS1956.0.3 0.4038 1304 4453 5148 3.46343111245044e-201 3.07530880654823e-199 agent control dexamethasone disease state normal amyotophic lateral sclerosis GDS715.0.3.18 GDS715.0.7.18 -0.4037 592 136 678 5.79877588480318e-28 3.30090053052764e-27 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent none 4,5-dianilinophthalimide GDS1353.0.1.2 GDS1956.0.5 0.4025 1304 2945 3895 1.22915493717874e-151 6.6450448430012e-150 agent control dexamethasone disease state normal fascioscapulohumeral muscular dystrophy GDS2142.0.1 GDS2617.0.1 -0.4019 226 119 339 1.36608151555672e-14 4.48950325531272e-14 disease state normal mild cystic fibrosis disease state normal non-tumorigenic cancer cell GDS1956.0.3 GDS715.2.5.18 -0.4013 4453 3040 6279 1.14393426475091e-241 1.36217785294981e-239 disease state normal amyotophic lateral sclerosis agent negative control sulmazole GDS2341.0.1.5 GDS715.0.14.18 0.4013 136 141 276 4.20519700268232e-12 1.19723921729891e-11 agent untreated Type I IFN agent none R-(-)-apomorphine HCl GDS1926.0.2.4 GDS2367.3.4.1 0.4005 119 266 381 4.12721419908868e-16 1.46652532879742e-15 agent control LTD4 infection control adenovirus adenovirus carrying estrogen receptor beta GDS1259.0.1 GDS2200.0.2 0.3999 2867 1112 3668 6.26580275341772e-141 2.95749509901408e-139 disease state normal dermatomyositis disease state normal squamous cell carcinoma GDS2200.0.1 GDS2341.0.1.4 0.3996 649 217 845 9.72779199361346e-34 6.61910661903948e-33 disease state normal actinic keratosis agent untreated Type I IFN GDS1353.0.1.2 GDS2341.0.1.4 -0.3994 1304 217 1492 3.05567899234631e-58 3.86112148214784e-57 agent control dexamethasone agent untreated Type I IFN GDS1331.0.1 GDS715.0.5.18 -0.3993 1070 4478 5095 2.29236224446972e-194 1.92029968638576e-192 disease state normal presymptomatic agent none sulmazole GDS1062.2.3.0 GDS715.0.4.18 0.3986 483 5001 5378 2.82619296865538e-204 2.56570803775276e-202 disease state no metastasis metastasis agent none a-methyl-L-p-tyrosine GDS1956.0.5 GDS715.2.5.18 -0.3981 2945 3040 5307 4.6520264635895e-201 4.12832584610595e-199 disease state normal fascioscapulohumeral muscular dystrophy agent negative control sulmazole GDS1331.0.1 GDS2367.3.4.1 -0.3980 1070 266 1304 9.6694254638412e-51 1.02293860883045e-49 disease state normal presymptomatic infection control adenovirus adenovirus carrying estrogen receptor beta GDS2221.1.3 GDS2414.0.1.4 0.3973 940 129 1046 7.00170092209833e-41 5.82189274686335e-40 agent vehicle lipopolysaccharide agent control trophoblast conditioned medium GDS715.0.3.18 GDS715.2.6.18 -0.3969 592 582 1053 4.66812243506011e-41 3.90239332943286e-40 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent negative control 16-ketoestradiol GDS1355.0.1 GDS1574.8.9.11 -0.3965 433 567 985 1.97460255854769e-38 1.53789351315606e-37 disease state normal pancreatic ductal carcinoma agent control endotoxin GDS715.0.12.18 GDS715.2.4.18 -0.3965 131 3836 3936 2.47394731909875e-148 1.28511951686563e-146 agent none 5-fluorouracil agent negative control a-methyl-L-p-tyrosine GDS1543.0.1 GDS715.0.3.18 0.3958 466 592 1041 2.25355512558357e-40 1.84915805177101e-39 agent control tumor necrosis factor agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1220.0.1.3 GDS1574.8.9.11 -0.3955 1705 567 2189 7.12355440976736e-83 1.46415892724606e-81 disease state normal malignant pleural mesothelioma agent control endotoxin GDS1259.0.1 GDS1353.0.1.2 -0.3954 2867 1304 3706 6.03859603481707e-139 2.78953577136596e-137 disease state normal dermatomyositis agent control dexamethasone GDS651.0.1 GDS715.2.5.18 0.3948 4221 3040 6318 1.02433715514135e-234 1.1805047498667e-232 disease state normal idiopathic dilated agent negative control sulmazole GDS1326.2.3.1 GDS715.0.11.18 0.3945 181 183 357 9.63060300354821e-15 3.19124947664259e-14 agent control E2 agent none scopolamine methyl bromide GDS2617.0.1 GDS715.0.6.18 -0.3945 119 1378 1485 1.74843171295755e-56 2.12640625200748e-55 disease state normal non-tumorigenic cancer cell agent none 16-ketoestradiol GDS1574.8.9.11 GDS2153.0.1 -0.3943 567 1932 2378 2.71865153123659e-89 6.27847776458692e-88 agent control endotoxin disease state normal dermatomyositis GDS1926.0.3.4 GDS2367.0.2.3 -0.3940 135 282 412 9.44027368860648e-17 3.45619485330261e-16 agent control LTD4 and thrombin agent vehicle tamoxifen GDS2221.0.3 GDS2414.0.1.4 0.3933 970 129 1073 5.11108426949235e-41 4.26620881050328e-40 agent untreated lipopolysaccharide agent control trophoblast conditioned medium GDS2635.0.3 GDS715.2.4.18 -0.3931 300 3836 4081 6.61972785516372e-151 3.5451413637387e-149 disease state lobular control invasive ductal carcinoma agent negative control a-methyl-L-p-tyrosine GDS1926.0.2.4 GDS2367.0.2.3 -0.3928 119 282 397 4.26034717209518e-16 1.51274928668562e-15 agent control LTD4 agent vehicle tamoxifen GDS2200.0.2 GDS2617.0.2 0.3928 1112 503 1523 2.32428616979722e-57 2.88276425307405e-56 disease state normal squamous cell carcinoma disease state normal tumorigenic cancer cell GDS1062.2.3.0 GDS1220.0.1.3 -0.3926 483 1705 2110 1.04790693803373e-78 1.99782607257856e-77 disease state no metastasis metastasis disease state normal malignant pleural mesothelioma GDS1353.0.1.2 GDS2216.0.1.5 0.3925 1304 244 1500 1.98367052808829e-56 2.40831373860887e-55 agent control dexamethasone agent control LPS GDS715.0.7.18 GDS715.0.9.18 0.3925 136 3151 3257 1.99219140567663e-120 7.32237510707927e-119 agent none 4,5-dianilinophthalimide agent none 5-fluorouridine GDS1331.0.2 GDS1353.0.1.2 0.3924 3398 1304 4094 8.40925033232897e-151 4.49881114682107e-149 disease state normal symptomatic agent control dexamethasone GDS1956.0.1 GDS1956.0.10 0.3922 4393 2334 5820 2.59132173231881e-213 2.54128255957334e-211 disease state normal acute quadriplegic myopathy disease state normal dysferlin mutation GDS1259.0.1 GDS715.2.5.18 0.3918 2867 3040 4897 2.09598815737596e-179 1.53018350420573e-177 disease state normal dermatomyositis agent negative control sulmazole GDS1259.0.1 GDS715.2.6.18 0.3918 2867 582 3276 1.17444334571507e-120 4.33950149377933e-119 disease state normal dermatomyositis agent negative control 16-ketoestradiol GDS1062.2.3.0 GDS2341.0.1.5 -0.3912 483 136 614 6.89615257180721e-24 3.40077119180335e-23 disease state no metastasis metastasis agent untreated Type I IFN GDS2057.0.1.3 GDS2367.0.2.3 -0.3910 133 282 407 2.56323583191278e-16 9.1887549231045e-16 agent control DHT agent vehicle tamoxifen GDS2057.0.2.3 GDS2635.0.2 0.3907 117 263 370 6.08809121785874e-15 2.03914151063302e-14 agent control RTI-018 disease state lobular control invasive lobular carcinoma GDS1353.0.1.2 GDS1543.0.1 -0.3906 1304 466 1682 2.01369166936104e-62 2.78766995102051e-61 agent control dexamethasone agent control tumor necrosis factor GDS1543.0.1 GDS715.2.3.18 0.3905 466 266 721 1.11311134872374e-27 6.27411937621721e-27 agent control tumor necrosis factor agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1543.0.1 GDS715.2.6.18 0.3905 466 582 1025 1.1193526148042e-38 8.77296013808116e-38 agent control tumor necrosis factor agent negative control 16-ketoestradiol GDS1062.2.3.0 GDS1574.8.9.10 -0.3901 483 360 833 1.14437505508332e-31 7.32660252475112e-31 disease state no metastasis metastasis agent control endotoxin GDS1971.0.1 GDS2255.3.4.1 0.3899 1356 267 1515 3.48614733968204e-56 4.2062230671096e-55 disease state healthy uncomplicated malaria agent untreated endotoxin GDS715.0.11.18 GDS715.2.4.18 -0.3899 183 3836 3997 2.8694301609901e-145 1.43348877201682e-143 agent none scopolamine methyl bromide agent negative control a-methyl-L-p-tyrosine GDS2164.0.1 GDS715.0.3.18 0.3898 1302 592 1776 1.57669201372038e-65 2.33289030004568e-64 agent control SIV-Nef agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1353.0.1.2 GDS2367.0.1.3 -0.3896 1304 187 1441 1.94721005298946e-53 2.20010707804639e-52 agent control dexamethasone agent vehicle estradiol GDS1439.0.2 GDS2250.0.3 0.3879 3178 232 3265 1.03206391974394e-117 3.65551210658399e-116 disease state benign metastatic disease state normal basal-like cancer GDS2057.0.1.3 GDS715.0.11.18 0.3878 133 183 314 1.03936317095914e-12 3.06756947671637e-12 agent control DHT agent none scopolamine methyl bromide GDS2341.0.1.5 GDS715.0.11.18 0.3877 136 183 314 1.0545293967787e-12 3.11119785068961e-12 agent untreated Type I IFN agent none scopolamine methyl bromide GDS1326.2.3.1 GDS1353.0.1.2 -0.3864 181 1304 1466 2.11291327999129e-53 2.38575559645013e-52 agent control E2 agent control dexamethasone GDS651.0.1 GDS715.0.9.18 -0.3863 4221 3151 6401 7.06900963943282e-227 7.65941792878408e-225 disease state normal idiopathic dilated agent none 5-fluorouridine GDS1062.2.3.0 GDS2153.0.1 -0.3860 483 1932 2332 1.00204354284787e-83 2.09083785527644e-82 disease state no metastasis metastasis disease state normal dermatomyositis GDS1259.0.1 GDS2635.0.2 0.3858 2867 263 3062 3.07424899843759e-109 9.64222539380214e-108 disease state normal dermatomyositis disease state lobular control invasive lobular carcinoma GDS1574.8.9.11 GDS2239.0.1 -0.3857 567 332 882 1.15460805610829e-32 7.59681303069928e-32 agent control endotoxin agent control hepatitis C virus core protein GDS1615.0.2 GDS1971.0.2 0.3852 3399 953 3917 9.47196327516065e-139 4.36119000250116e-137 disease state normal Crohn's disease disease state healthy complicated malaria GDS651.0.1 GDS715.2.9.18 -0.3850 4221 3560 6669 1.38721082590776e-234 1.59631144379643e-232 disease state normal idiopathic dilated agent negative control 5-fluorouridine GDS2428.0.1.3 GDS715.2.3.18 0.3849 181 266 438 6.46333544079505e-17 2.38473201609693e-16 agent untreated 5-aza-dC agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1353.0.1.2 GDS2367.3.4.2 0.3844 1304 691 1763 3.55683455674376e-63 4.99944965441624e-62 agent control dexamethasone infection control adenovirus adenovirus carrying estrogen receptor beta GDS1259.0.1 GDS2635.0.3 0.3836 2867 300 3084 1.11782324430839e-108 3.48047173631781e-107 disease state normal dermatomyositis disease state lobular control invasive ductal carcinoma GDS2164.0.1 GDS2635.0.3 0.3833 1302 300 1573 3.24755111234354e-56 3.92233976913598e-55 agent control SIV-Nef disease state lobular control invasive ductal carcinoma GDS2221.1.3 GDS2341.0.3.5 0.3829 940 741 1509 7.02782678416614e-54 8.02062437255774e-53 agent vehicle lipopolysaccharide agent untreated Types I and II IFNs GDS266.0.1.2 GDS715.0.5.18 0.3818 407 4478 4779 1.10897940149024e-165 6.9835442148605e-164 disease state no atopy atopy agent none sulmazole GDS1956.0.1 GDS715.0.5.18 -0.3816 4393 4478 7446 9.8195671507394e-257 1.27157435598286e-254 disease state normal acute quadriplegic myopathy agent none sulmazole GDS2617.0.2 GDS2649.2.5.1 0.3816 503 1267 1629 1.2934943485905e-57 1.61339197936622e-56 disease state normal tumorigenic cancer cell disease state uninfected early HIV infection GDS2057.0.1.3 GDS2635.0.2 0.3805 133 263 388 8.17771968061802e-15 2.72016391027796e-14 agent control DHT disease state lobular control invasive lobular carcinoma GDS1615.0.1 GDS1971.0.1 0.3803 2228 1356 3152 5.19891712814701e-109 1.62630709418931e-107 disease state normal ulcerative colitis disease state healthy uncomplicated malaria GDS2221.0.3 GDS2341.0.3.5 0.3802 970 741 1538 4.4842236866784e-54 5.14132272391806e-53 agent untreated lipopolysaccharide agent untreated Types I and II IFNs GDS1376.2.3.1 GDS1574.8.9.11 -0.3800 805 567 1323 1.05814840976758e-46 1.02093805900248e-45 disease state normal thrombocythemia agent control endotoxin GDS2213.0.1 GDS715.2.4.18 0.3795 1016 3836 4521 7.86812285522733e-155 4.39884305984258e-153 agent untreated 5-aza-dC agent negative control a-methyl-L-p-tyrosine GDS2200.0.2 GDS2367.0.2.3 0.3794 1112 282 1347 2.3125670140639e-47 2.26589013664204e-46 disease state normal squamous cell carcinoma agent vehicle tamoxifen GDS1259.0.1 GDS2362.6.7.2.5 -0.3793 2867 797 3461 7.61149429643062e-119 2.74007182538021e-117 disease state normal dermatomyositis agent untreated chloroguine treated GDS2142.0.2 GDS715.2.6.18 -0.3791 604 582 1148 1.51724039501514e-40 1.2515102372053e-39 disease state normal severe cystic fibrosis agent negative control 16-ketoestradiol GDS1062.2.3.0 GDS715.2.6.18 0.3787 483 582 1040 8.34061539739612e-37 6.18618548515346e-36 disease state no metastasis metastasis agent negative control 16-ketoestradiol GDS2221.0.2 GDS2414.0.1.4 0.3775 1338 129 1439 5.90022869179163e-50 6.12739842271908e-49 agent untreated galectin-1 agent control trophoblast conditioned medium GDS1331.0.2 GDS1956.0.3 0.3771 3398 4453 6347 1.21331454288919e-213 1.19444986440697e-211 disease state normal symptomatic disease state normal amyotophic lateral sclerosis GDS2221.1.2 GDS2414.0.1.4 0.3768 1258 129 1358 4.67257544558577e-47 4.54500237416565e-46 agent vehicle galectin-1 agent control trophoblast conditioned medium GDS1392.0.1 GDS2635.0.3 -0.3766 413 300 706 3.28639383799429e-25 1.70255861912957e-24 disease state normal rheumatoid arthritis, on methotrexate disease state lobular control invasive ductal carcinoma GDS715.0.14.18 GDS715.2.6.18 -0.3764 141 582 703 4.40763981510975e-25 2.27272853739121e-24 agent none R-(-)-apomorphine HCl agent negative control 16-ketoestradiol GDS1062.2.3.0 GDS2852.0.1.5 -0.3761 483 538 989 1.37962269398674e-34 9.61255043556487e-34 disease state no metastasis metastasis agent control IL-13 GDS1926.0.2.4 GDS715.0.6.18 0.3760 119 1378 1479 7.14094874606237e-51 7.57895931977892e-50 agent control LTD4 agent none 16-ketoestradiol GDS2057.0.2.3 GDS715.0.6.18 0.3757 117 1378 1482 6.89863103447051e-51 7.3248078487652e-50 agent control RTI-018 agent none 16-ketoestradiol GDS2142.0.1 GDS715.0.6.18 -0.3756 226 1378 1578 4.82276578837695e-54 5.52535884547094e-53 disease state normal mild cystic fibrosis agent none 16-ketoestradiol GDS2367.0.1.3 GDS2428.0.1.3 -0.3749 187 181 363 1.47488502386277e-13 4.58388205568745e-13 agent vehicle estradiol agent untreated 5-aza-dC GDS2057.0.1.3 GDS2142.0.1 0.3746 133 226 356 2.651807674716e-13 8.11153826648554e-13 agent control DHT disease state normal mild cystic fibrosis GDS1392.0.1 GDS715.2.5.18 -0.3743 413 3040 3326 4.16043877268955e-111 1.33899586292554e-109 disease state normal rheumatoid arthritis, on methotrexate agent negative control sulmazole GDS266.0.1.2 GDS715.2.13.18 -0.3742 407 317 713 4.06145187175726e-25 2.09731277667596e-24 disease state no atopy atopy agent negative control 8-(3-chlorostyryl) caffeine GDS1282.0.1 GDS1353.0.1.2 -0.3740 1006 1304 2229 6.13361569825242e-75 1.09051072421978e-73 disease state control Wilms' tumor agent control dexamethasone GDS2250.0.1 GDS2737.0.1.3 0.3737 160 739 847 1.8308491171093e-29 1.09664539131997e-28 disease state normal non-basal-like cancer disease state normal endometriosis GDS1331.0.2 GDS715.2.4.18 -0.3733 3398 3836 5559 2.33637484173033e-183 1.76337071792495e-181 disease state normal symptomatic agent negative control a-methyl-L-p-tyrosine GDS1326.2.3.1 GDS266.0.1.2 -0.3732 181 407 574 2.07639431539246e-20 8.96192837156853e-20 agent control E2 disease state no atopy atopy GDS1397.0.1 GDS715.0.8.16 -0.3731 1060 109 1158 1.47470629191642e-39 1.18302505073507e-38 agent untreated HIV agent none 1,10-phenanthroline GDS2635.0.3 GDS2737.0.1.3 0.3730 300 739 1004 1.70227431627951e-34 1.18311856777025e-33 disease state lobular control invasive ductal carcinoma disease state normal endometriosis GDS1926.0.3.4 GDS715.0.6.18 0.3728 135 1378 1499 1.25450997750671e-50 1.3230683553173e-49 agent control LTD4 and thrombin agent none 16-ketoestradiol GDS1392.0.1 GDS2057.0.1.3 0.3726 413 133 539 3.4033780664602e-19 1.3960630946639e-18 disease state normal rheumatoid arthritis, on methotrexate agent control DHT GDS1574.8.9.13 GDS2221.0.2 0.3724 1931 1338 2906 2.85813632712821e-96 7.39227863782677e-95 agent control endotoxin agent untreated galectin-1 GDS1259.0.1 GDS2164.0.1 -0.3715 2867 1302 3700 1.94429038361956e-121 7.25191509304828e-120 disease state normal dermatomyositis agent control SIV-Nef GDS1543.0.1 GDS2221.1.3 0.3705 466 940 1306 9.19850405247821e-44 8.25192500975623e-43 agent control tumor necrosis factor agent vehicle lipopolysaccharide GDS1331.0.1 GDS715.0.4.18 -0.3703 1070 5001 5597 1.89360540256743e-181 1.40644078849868e-179 disease state normal presymptomatic agent none a-methyl-L-p-tyrosine GDS1392.0.1 GDS2635.0.2 -0.3698 413 263 667 4.8245355139104e-23 2.30540782982327e-22 disease state normal rheumatoid arthritis, on methotrexate disease state lobular control invasive lobular carcinoma GDS2250.0.3 GDS2737.0.1.3 0.3698 232 739 901 1.40254166646564e-30 8.68163280539652e-30 disease state normal basal-like cancer disease state normal endometriosis GDS651.0.1 GDS715.0.5.18 0.3698 4221 4478 7254 6.7747818836305e-234 7.76695119025404e-232 disease state normal idiopathic dilated agent none sulmazole GDS2367.3.4.1 GDS2418.0.1 -0.3695 266 2548 2659 8.421141505351e-87 1.85890854704895e-85 infection control adenovirus adenovirus carrying estrogen receptor beta disease state control vulvar intraepithelial neoplasia GDS715.0.9.18 GDS715.2.10.18 0.3694 3151 132 3197 6.24412344455845e-104 1.80645805205376e-102 agent none 5-fluorouridine agent negative control pergolide methanesulfonate GDS2200.0.2 GDS2367.3.4.2 -0.3689 1112 691 1718 1.61174602441367e-56 1.96156644151406e-55 disease state normal squamous cell carcinoma infection control adenovirus adenovirus carrying estrogen receptor beta GDS2611.0.2.9 GDS2611.0.3.9 0.3689 640 284 829 4.01040337252367e-28 2.29510454816252e-27 agent untreated IL-1b agent untreated IFN-gamma GDS2221.1.3 GDS2341.0.1.4 0.3685 940 217 1091 2.00898953119786e-36 1.47562575997414e-35 agent vehicle lipopolysaccharide agent untreated Type I IFN GDS2635.0.2 GDS715.2.5.18 -0.3685 263 3040 3261 1.98321516996155e-105 5.87441780724789e-104 disease state lobular control invasive lobular carcinoma agent negative control sulmazole GDS1956.0.3 GDS715.0.9.18 0.3681 4453 3151 6390 2.9112498941237e-204 2.64136801477121e-202 disease state normal amyotophic lateral sclerosis agent none 5-fluorouridine GDS1282.0.1 GDS1956.0.4 0.3678 1006 1090 1998 4.87699007421234e-65 7.13310340566247e-64 disease state control Wilms' tumor disease state normal spastic paraplegia GDS1331.0.2 GDS715.0.10.18 0.3678 3398 158 3498 1.6783263887756e-112 5.52628389652992e-111 disease state normal symptomatic agent none pergolide methanesulfonate GDS1574.8.9.11 GDS1746.2.4.0 0.3677 567 222 776 2.97958514138539e-26 1.59969876875006e-25 agent control endotoxin disease state normal basaloid GDS2142.0.2 GDS2635.0.2 -0.3675 604 263 856 9.15069700483447e-29 5.35872934850584e-28 disease state normal severe cystic fibrosis disease state lobular control invasive lobular carcinoma GDS1392.0.1 GDS2617.0.2 0.3673 413 503 896 5.30433807007317e-30 3.22653221137971e-29 disease state normal rheumatoid arthritis, on methotrexate disease state normal tumorigenic cancer cell GDS2635.0.2 GDS715.2.4.18 -0.3672 263 3836 4057 9.99035040684336e-130 4.11943522827135e-128 disease state lobular control invasive lobular carcinoma agent negative control a-methyl-L-p-tyrosine GDS1574.8.9.13 GDS715.0.4.18 0.3671 1931 5001 5933 1.05942703524334e-188 8.399493472024e-187 agent control endotoxin agent none a-methyl-L-p-tyrosine GDS2142.0.2 GDS2635.0.3 -0.3670 604 300 887 1.14630018059791e-29 6.90481093817818e-29 disease state normal severe cystic fibrosis disease state lobular control invasive ductal carcinoma GDS1331.0.1 GDS2153.0.1 0.3662 1070 1932 2786 3.70030388215388e-89 8.52633105453893e-88 disease state normal presymptomatic disease state normal dermatomyositis GDS1220.0.1.3 GDS1956.0.1 0.3659 1705 4393 5419 2.49769866354703e-171 1.6727550176578e-169 disease state normal malignant pleural mesothelioma disease state normal acute quadriplegic myopathy GDS1956.0.4 GDS715.0.6.18 -0.3658 1090 1378 2323 1.79844941798461e-74 3.16751511947493e-73 disease state normal spastic paraplegia agent none 16-ketoestradiol GDS715.0.11.18 GDS715.0.9.18 0.3658 183 3151 3293 8.35431446353144e-105 2.45009422204925e-103 agent none scopolamine methyl bromide agent none 5-fluorouridine GDS1956.0.5 GDS715.0.9.18 0.3657 2945 3151 5368 1.54330896270635e-169 1.01417257159599e-167 disease state normal fascioscapulohumeral muscular dystrophy agent none 5-fluorouridine GDS1447.0.1 GDS1574.8.9.11 0.3655 242 567 790 2.23948913778887e-26 1.20854614567664e-25 agent control vanadium agent control endotoxin GDS715.0.1.18 GDS715.0.15.18 0.3654 3116 452 3319 2.25333132402882e-105 6.66426351311654e-104 agent none positive control agent none cyclazosin HCl GDS1331.0.1 GDS2142.0.1 -0.3652 1070 226 1278 1.32372630361879e-41 1.12225025156869e-40 disease state normal presymptomatic disease state normal mild cystic fibrosis GDS1956.0.5 GDS715.2.4.18 -0.3652 2945 3836 5855 3.34251887164006e-184 2.54269711836112e-182 disease state normal fascioscapulohumeral muscular dystrophy agent negative control a-methyl-L-p-tyrosine GDS1331.0.2 GDS715.2.5.18 -0.3647 3398 3040 5108 1.73923340340064e-160 1.03233147093628e-158 disease state normal symptomatic agent negative control sulmazole GDS1956.0.1 GDS715.0.9.18 0.3646 4393 3151 6556 2.68979298000933e-205 2.46074159796691e-203 disease state normal acute quadriplegic myopathy agent none 5-fluorouridine GDS715.0.12.18 GDS715.2.5.18 -0.3646 131 3040 3138 2.86710825846233e-99 7.7432685526483e-98 agent none 5-fluorouracil agent negative control sulmazole GDS1615.0.2 GDS715.1.2.18 0.3644 3399 2226 4763 1.6176531237813e-149 8.51512056315443e-148 disease state normal Crohn's disease agent negative control positive control GDS1574.8.9.13 GDS715.0.5.18 0.3640 1931 4478 5510 2.94767650864467e-172 1.99493932068828e-170 agent control endotoxin agent none sulmazole GDS2341.0.2.4 GDS715.0.3.18 0.3639 300 592 879 6.5189941061343e-29 3.83435206303285e-28 agent untreated Type II IFN agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2250.0.1 GDS715.2.6.18 -0.3638 160 582 733 2.34438647715062e-24 1.17592247921171e-23 disease state normal non-basal-like cancer agent negative control 16-ketoestradiol GDS2414.0.1.4 GDS715.2.3.18 -0.3634 129 266 389 1.3745705863724e-13 4.28091741299164e-13 agent control trophoblast conditioned medium agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1282.0.1 GDS2635.0.3 0.3627 1006 300 1267 1.10845370583944e-40 9.1776035489239e-40 disease state control Wilms' tumor disease state lobular control invasive ductal carcinoma GDS1543.0.1 GDS2221.0.3 0.3627 466 970 1331 1.18556178850075e-42 1.03310269289948e-41 agent control tumor necrosis factor agent untreated lipopolysaccharide GDS1326.2.3.1 GDS2635.0.2 0.3626 181 263 439 4.35755898642071e-15 1.47049025113469e-14 agent control E2 disease state lobular control invasive lobular carcinoma GDS2200.0.2 GDS2250.0.3 0.3617 1112 232 1246 8.2778163692503e-40 6.68653893409435e-39 disease state normal squamous cell carcinoma disease state normal basal-like cancer GDS2250.0.1 GDS2635.0.2 0.3615 160 263 387 2.1653072820846e-13 6.66031340409089e-13 disease state normal non-basal-like cancer disease state lobular control invasive lobular carcinoma GDS1746.2.4.0 GDS715.0.7.18 -0.3610 222 136 355 2.28709753345879e-12 6.61383625706059e-12 disease state normal basaloid agent none 4,5-dianilinophthalimide GDS1956.0.10 GDS1956.0.4 0.3609 2334 1090 3038 4.01860327570847e-94 1.00314113596712e-92 disease state normal dysferlin mutation disease state normal spastic paraplegia GDS1746.2.4.0 GDS715.0.3.18 -0.3608 222 592 803 4.27880272946871e-26 2.28496086363037e-25 disease state normal basaloid agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2021.0.2 GDS715.0.3.18 0.3608 314 592 888 1.08539551412802e-28 6.33809251613988e-28 agent control nebivolol agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1956.0.1 GDS1956.0.7 0.3606 4393 1627 5330 2.0764571627731e-163 1.27120694752426e-161 disease state normal acute quadriplegic myopathy disease state normal Becker muscular dystrophy GDS2057.0.2.3 GDS2142.0.1 0.3590 117 226 340 8.84947090032893e-12 2.4702452114571e-11 agent control RTI-018 disease state normal mild cystic fibrosis GDS1353.0.1.2 GDS1850.0.1 -0.3589 1304 731 1924 1.42029220424092e-59 1.85259195402073e-58 agent control dexamethasone disease state healthy carious GDS2617.0.1 GDS2649.2.5.1 0.3589 119 1267 1355 1.84385579516856e-42 1.59932011575309e-41 disease state normal non-tumorigenic cancer cell disease state uninfected early HIV infection GDS2367.0.2.3 GDS2428.0.1.3 -0.3584 282 181 458 2.50162108351752e-15 8.55496761285753e-15 agent vehicle tamoxifen agent untreated 5-aza-dC GDS1392.0.1 GDS2341.0.1.4 0.3583 413 217 619 3.45814013040893e-20 1.47929848478017e-19 disease state normal rheumatoid arthritis, on methotrexate agent untreated Type I IFN GDS1956.0.1 GDS715.2.9.18 0.3582 4393 3560 6832 5.90610609144629e-206 5.42249864815025e-204 disease state normal acute quadriplegic myopathy agent negative control 5-fluorouridine GDS1543.0.1 GDS2367.0.2.3 -0.3572 466 282 716 5.68740521408267e-23 2.70907073498525e-22 agent control tumor necrosis factor agent vehicle tamoxifen GDS1259.0.1 GDS715.2.3.18 0.3571 2867 266 3067 6.49227527416781e-93 1.59198038989797e-91 disease state normal dermatomyositis agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1543.0.1 GDS2221.0.2 0.3571 466 1338 1650 8.34009100778122e-51 8.83338725661114e-50 agent control tumor necrosis factor agent untreated galectin-1 GDS715.0.14.18 GDS715.2.9.18 0.3567 141 3560 3656 3.86294568619975e-110 1.22607940760674e-108 agent none R-(-)-apomorphine HCl agent negative control 5-fluorouridine GDS1956.0.4 GDS2118.0.2 0.3566 1090 2118 2971 8.45792636965676e-90 1.97310971821418e-88 disease state normal spastic paraplegia disease state normal refractory anemia with ringed sideroblasts GDS1543.0.1 GDS2200.0.1 0.3560 466 649 1083 1.04695903201171e-33 7.11850236949945e-33 agent control tumor necrosis factor disease state normal actinic keratosis GDS1331.0.1 GDS715.0.9.18 0.3558 1070 3151 3884 2.85986666521008e-116 9.95993586283627e-115 disease state normal presymptomatic agent none 5-fluorouridine GDS1259.0.1 GDS715.0.7.18 0.3555 2867 136 2974 2.62232829524154e-89 6.05875433907784e-88 disease state normal dermatomyositis agent none 4,5-dianilinophthalimide GDS2428.0.1.3 GDS715.2.6.18 0.3554 181 582 751 8.880024384796e-24 4.36386365365311e-23 agent untreated 5-aza-dC agent negative control 16-ketoestradiol GDS1543.0.1 GDS2221.1.2 0.3551 466 1258 1582 3.21107525027371e-48 3.20874706554341e-47 agent control tumor necrosis factor agent vehicle galectin-1 GDS1376.2.3.1 GDS1956.0.5 0.3547 805 2945 3521 6.7861575548461e-105 1.99133416701703e-103 disease state normal thrombocythemia disease state normal fascioscapulohumeral muscular dystrophy GDS2250.0.1 GDS715.2.4.18 -0.3544 160 3836 3953 2.52540493835178e-117 8.90795569673771e-116 disease state normal non-basal-like cancer agent negative control a-methyl-L-p-tyrosine GDS2213.0.1 GDS715.0.4.18 0.3541 1016 5001 5570 3.12759028260615e-164 1.93860592029427e-162 agent untreated 5-aza-dC agent none a-methyl-L-p-tyrosine GDS1259.0.1 GDS1956.0.4 0.3540 2867 1090 3663 1.3454665855062e-108 4.18249913376375e-107 disease state normal dermatomyositis disease state normal spastic paraplegia GDS1392.0.1 GDS2200.0.1 -0.3540 413 649 1037 5.62954073844278e-32 3.63425882736157e-31 disease state normal rheumatoid arthritis, on methotrexate disease state normal actinic keratosis GDS2341.0.3.4 GDS2649.3.5.0 0.3529 494 229 671 4.12368124732472e-21 1.8304679919815e-20 agent untreated Types I and II IFNs disease state uninfected chronic HIV infection GDS715.0.15.18 GDS715.0.7.18 0.3526 452 136 556 1.01420222266648e-17 3.89113095649157e-17 agent none cyclazosin HCl agent none 4,5-dianilinophthalimide GDS1353.0.1.2 GDS2021.0.2 -0.3524 1304 314 1559 8.40409402671935e-47 8.13148960300228e-46 agent control dexamethasone agent control nebivolol GDS1746.2.4.0 GDS715.2.3.18 -0.3522 222 266 480 1.82897244952837e-15 6.29802854987775e-15 disease state normal basaloid agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1574.8.9.11 GDS2341.0.1.4 -0.3518 567 217 772 6.57094234592811e-24 3.24278573321827e-23 agent control endotoxin agent untreated Type I IFN GDS1259.0.1 GDS715.0.1.18 0.3513 2867 3116 5060 6.8218917266769e-147 3.4756947934169e-145 disease state normal dermatomyositis agent none positive control GDS1574.8.9.12 GDS1956.0.4 0.3512 2152 1090 3059 1.69466669033343e-89 3.92427317193107e-88 agent control endotoxin disease state normal spastic paraplegia GDS2118.0.1 GDS2617.0.1 0.3508 934 119 1030 3.42120611071485e-31 2.15769154128103e-30 disease state normal refractory anemia disease state normal non-tumorigenic cancer cell GDS2057.0.1.4 GDS715.1.2.18 -0.3508 292 2226 2403 1.58606581592361e-70 2.59184709050877e-69 agent control DHT agent negative control positive control GDS2142.0.2 GDS2367.0.2.3 0.3502 604 282 876 1.12711959797961e-26 6.14433759341041e-26 disease state normal severe cystic fibrosis agent vehicle tamoxifen GDS1257.0.2 GDS1353.0.1.2 0.3495 850 1304 2025 2.97464659496982e-59 3.85393161715201e-58 disease state normal SCD steady state agent control dexamethasone GDS1543.0.1 GDS715.0.6.18 0.3494 466 1378 1801 7.36012124799031e-53 8.20404866910601e-52 agent control tumor necrosis factor agent none 16-ketoestradiol GDS1353.0.1.2 GDS2213.0.3 -0.3489 1304 1316 2454 3.5515726762504e-71 5.86726987587623e-70 agent control dexamethasone agent untreated 5-aza-dC plus TSA GDS1062.2.3.0 GDS715.0.7.18 0.3487 483 136 613 5.76202200003037e-19 2.34044384242058e-18 disease state no metastasis metastasis agent none 4,5-dianilinophthalimide GDS1956.0.5 GDS715.2.9.18 0.3485 2945 3560 5684 5.24004662708169e-162 3.16144588618936e-160 disease state normal fascioscapulohumeral muscular dystrophy agent negative control 5-fluorouridine GDS1392.0.1 GDS715.2.4.18 -0.3482 413 3836 4103 2.85497472498154e-117 1.00589373192417e-115 disease state normal rheumatoid arthritis, on methotrexate agent negative control a-methyl-L-p-tyrosine GDS1259.0.1 GDS715.2.4.18 0.3478 2867 3836 5407 1.48078496290352e-153 8.1776872500658e-152 disease state normal dermatomyositis agent negative control a-methyl-L-p-tyrosine GDS1453.0.1 GDS885.0.1 0.3475 432 1657 1974 4.01466339266246e-57 4.95416234375716e-56 agent untreated camptothecin agent control campthotecin GDS715.2.3.18 GDS715.2.6.18 -0.3470 266 582 767 4.00860011626124e-23 1.92135629724592e-22 agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent negative control 16-ketoestradiol GDS1574.8.9.10 GDS2428.0.1.3 -0.3469 360 181 535 1.42030405995032e-16 5.15698100827365e-16 agent control endotoxin agent untreated 5-aza-dC GDS2213.0.3 GDS715.2.4.18 0.3468 1316 3836 4655 1.13736552660675e-131 4.79775942582652e-130 agent untreated 5-aza-dC plus TSA agent negative control a-methyl-L-p-tyrosine GDS1259.0.1 GDS2221.1.3 0.3461 2867 940 3431 3.90353591549225e-97 1.02318816582202e-95 disease state normal dermatomyositis agent vehicle lipopolysaccharide GDS2341.0.2.4 GDS2635.0.2 0.3461 300 263 555 4.61713569268827e-17 1.71559828693425e-16 agent untreated Type II IFN disease state lobular control invasive lobular carcinoma GDS715.0.14.18 GDS715.2.3.18 -0.3457 141 266 389 2.32036068687827e-12 6.70700348256021e-12 agent none R-(-)-apomorphine HCl agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2367.0.2.3 GDS2397.0.1 -0.3453 282 580 803 6.68202662044855e-24 3.29676090651336e-23 agent vehicle tamoxifen disease state normal idiopathic myelofibrosis GDS1259.0.1 GDS2367.3.4.2 0.3452 2867 691 3290 1.02955680197125e-92 2.51897496663864e-91 disease state normal dermatomyositis infection control adenovirus adenovirus carrying estrogen receptor beta GDS2164.0.1 GDS2213.0.3 -0.3450 1302 1316 2427 8.68463957132769e-69 1.37440544430919e-67 agent control SIV-Nef agent untreated 5-aza-dC plus TSA GDS266.0.1.2 GDS715.0.15.18 0.3449 407 452 826 1.7432074869917e-24 8.78900603818398e-24 disease state no atopy atopy agent none cyclazosin HCl GDS2142.0.2 GDS715.0.14.18 -0.3448 604 141 731 7.80867380060055e-22 3.56328534934174e-21 disease state normal severe cystic fibrosis agent none R-(-)-apomorphine HCl GDS1326.2.3.1 GDS2142.0.1 0.3446 181 226 399 1.4437142403839e-12 4.22396589032411e-12 agent control E2 disease state normal mild cystic fibrosis GDS1259.0.1 GDS1392.0.1 0.3445 2867 413 3145 2.46787939907412e-88 5.60104890274126e-87 disease state normal dermatomyositis disease state normal rheumatoid arthritis, on methotrexate GDS1956.0.5 GDS715.0.5.18 -0.3440 2945 4478 6456 8.97594897874074e-179 6.52199842615517e-177 disease state normal fascioscapulohumeral muscular dystrophy agent none sulmazole GDS715.0.3.18 GDS715.2.9.18 0.3440 592 3560 3936 9.51332276897698e-110 3.00523181606343e-108 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent negative control 5-fluorouridine GDS1353.0.1.2 GDS715.0.8.16 0.3439 1304 109 1397 4.60688137907427e-40 3.7498076923267e-39 agent control dexamethasone agent none 1,10-phenanthroline GDS2057.0.2.3 GDS2635.0.3 0.3437 117 300 411 7.71504733036234e-13 2.29505120505035e-12 agent control RTI-018 disease state lobular control invasive ductal carcinoma GDS1956.0.11 GDS1956.0.5 0.3436 2145 2945 4426 7.11764447278552e-123 2.7059049618299e-121 disease state normal FKRP mutation disease state normal fascioscapulohumeral muscular dystrophy GDS1376.2.3.1 GDS2142.0.2 0.3435 805 604 1373 2.60863461499515e-39 2.07956402971615e-38 disease state normal thrombocythemia disease state normal severe cystic fibrosis GDS1331.0.1 GDS1376.2.3.1 0.3433 1070 805 1777 2.55019264328593e-50 2.67144364246391e-49 disease state normal presymptomatic disease state normal thrombocythemia GDS2216.0.1.5 GDS2414.0.1.4 -0.3429 244 129 370 1.20053794367079e-11 3.32245470889112e-11 agent control LPS agent control trophoblast conditioned medium GDS2255.3.4.1 GDS715.0.3.18 0.3425 267 592 851 7.85788577082355e-25 4.0136186052155e-24 agent untreated endotoxin agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1259.0.1 GDS715.0.5.18 0.3422 2867 4478 5987 4.14516888130173e-164 2.56521118103404e-162 disease state normal dermatomyositis agent none sulmazole GDS715.0.7.18 GDS715.2.15.18 0.3416 136 356 472 2.30123187757015e-14 7.4737749863061e-14 agent none 4,5-dianilinophthalimide agent negative control cyclazosin HCl GDS2142.0.2 GDS2367.0.1.3 0.3415 604 187 783 7.72985704050188e-23 3.6640380160547e-22 disease state normal severe cystic fibrosis agent vehicle estradiol GDS2221.0.3 GDS2341.0.2.5 0.3415 970 579 1414 5.89735259868735e-40 4.78275092457649e-39 agent untreated lipopolysaccharide agent untreated Type II IFN GDS1062.2.3.0 GDS715.0.9.18 -0.3414 483 3151 3576 2.59934483881287e-98 6.9277594910282e-97 disease state no metastasis metastasis agent none 5-fluorouridine GDS715.0.3.18 GDS715.2.4.18 -0.3412 592 3836 4165 4.69705831692402e-114 1.57800133429542e-112 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent negative control a-methyl-L-p-tyrosine GDS1050.0.1.2 GDS1331.0.2 0.3404 763 3398 3888 4.49879817323277e-106 1.34577858420049e-104 disease state normal polycystic ovary syndrome disease state normal symptomatic GDS2164.0.1 GDS715.0.7.18 0.3404 1302 136 1421 6.98265670082048e-40 5.65251142931581e-39 agent control SIV-Nef agent none 4,5-dianilinophthalimide GDS2221.0.3 GDS2341.0.1.5 0.3404 970 136 1050 6.76799809227422e-30 4.10323301359748e-29 agent untreated lipopolysaccharide agent untreated Type I IFN GDS1956.0.3 GDS651.0.1 -0.3403 4453 4221 6926 2.5137334762845e-187 1.97064781654716e-185 disease state normal amyotophic lateral sclerosis disease state normal idiopathic dilated GDS2213.0.3 GDS715.0.3.18 0.3402 1316 592 1817 1.82808755523582e-50 1.92062439368439e-49 agent untreated 5-aza-dC plus TSA agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2057.0.2.3 GDS2367.0.2.3 -0.3396 117 282 391 5.20855227260301e-12 1.47479974699469e-11 agent control RTI-018 agent vehicle tamoxifen GDS1850.0.1 GDS2414.0.1.4 0.3391 731 129 837 5.7258672951497e-24 2.83109173095346e-23 disease state healthy carious agent control trophoblast conditioned medium GDS1331.0.1 GDS715.2.9.18 0.3386 1070 3560 4271 4.71274984810618e-115 1.61032847236071e-113 disease state normal presymptomatic agent negative control 5-fluorouridine GDS1353.0.1.2 GDS1956.0.6 0.3386 1304 2160 3195 1.54238107232173e-86 3.38673371126876e-85 agent control dexamethasone disease state normal Emery-Dreifuss muscular dystrophy GDS715.0.6.18 GDS715.2.9.18 0.3384 1378 3560 4385 6.29402551923567e-118 2.23444849466626e-116 agent none 16-ketoestradiol agent negative control 5-fluorouridine GDS2341.0.3.4 GDS715.0.3.18 0.3376 494 592 1063 9.50320750088426e-30 5.73823505499539e-29 agent untreated Types I and II IFNs agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2250.0.1 GDS715.2.5.18 -0.3375 160 3040 3158 5.57088965032192e-85 1.18784146641813e-83 disease state normal non-basal-like cancer agent negative control sulmazole GDS1574.8.9.12 GDS1615.0.1 0.3373 2152 2228 3824 2.1974682314079e-102 6.21606492654998e-101 agent control endotoxin disease state normal ulcerative colitis GDS2213.0.1 GDS715.1.2.18 0.3369 1016 2226 2985 3.95923441273156e-80 7.75173614796583e-79 agent untreated 5-aza-dC agent negative control positive control GDS2213.0.1 GDS715.2.5.18 0.3368 1016 3040 3785 4.78629220411184e-101 1.32376001444584e-99 agent untreated 5-aza-dC agent negative control sulmazole GDS715.0.13.18 GDS715.2.6.18 -0.3367 274 582 819 3.69659482676103e-23 1.77429504385604e-22 agent none 8-(3-chlorostyryl) caffeine agent negative control 16-ketoestradiol GDS1453.0.1 GDS715.0.3.18 0.3365 432 592 995 9.133305243143e-28 5.16240580248218e-27 agent untreated camptothecin agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2341.0.3.4 GDS2367.3.4.2 0.3365 494 691 1152 6.79664645051324e-32 4.37797763756253e-31 agent untreated Types I and II IFNs infection control adenovirus adenovirus carrying estrogen receptor beta GDS2164.0.1 GDS2216.0.1.5 0.3363 1302 244 1492 8.9898895794344e-41 7.45654192143909e-40 agent control SIV-Nef agent control LPS GDS2142.0.2 GDS2191.0.1 -0.3362 604 942 1503 4.90153388883328e-41 4.09351683959476e-40 disease state normal severe cystic fibrosis disease state control bipolar disorder GDS1062.2.3.0 GDS1617.0.5 0.3362 483 1981 2431 2.60812318279275e-65 3.83798387040531e-64 disease state no metastasis metastasis agent control MGd/50uM zinc GDS1353.0.1.2 GDS2142.0.1 0.3360 1304 226 1501 6.19867467655432e-41 5.16030984838235e-40 agent control dexamethasone disease state normal mild cystic fibrosis GDS1353.0.1.2 GDS2341.0.3.4 -0.3360 1304 494 1691 6.67149894795207e-46 6.32278252136521e-45 agent control dexamethasone agent untreated Types I and II IFNs GDS1926.0.3.4 GDS2617.0.2 -0.3360 135 503 622 7.0147597743398e-18 2.71171892092333e-17 agent control LTD4 and thrombin disease state normal tumorigenic cancer cell GDS2200.0.1 GDS2367.0.2.3 0.3359 649 282 916 1.35170630607737e-25 7.0996759626035e-25 disease state normal actinic keratosis agent vehicle tamoxifen GDS2418.0.1 GDS2635.0.3 0.3359 2548 300 2741 2.83030260825059e-73 4.86520975060263e-72 disease state control vulvar intraepithelial neoplasia disease state lobular control invasive ductal carcinoma GDS2635.0.3 GDS266.0.1.2 0.3359 300 407 696 8.10394953668732e-20 3.40906316296588e-19 disease state lobular control invasive ductal carcinoma disease state no atopy atopy GDS1956.0.4 GDS2191.0.1 0.3356 1090 942 1868 2.09759246575131e-50 2.20046817227933e-49 disease state normal spastic paraplegia disease state control bipolar disorder GDS1375.0.2 GDS2250.0.3 0.3355 4896 232 4956 1.16965925778517e-130 4.87521465712134e-129 disease state normal malignant melanoma disease state normal basal-like cancer GDS1326.2.3.1 GDS715.2.5.18 0.3353 181 3040 3184 1.6498928766599e-84 3.49135755796366e-83 agent control E2 agent negative control sulmazole GDS2221.1.3 GDS2341.0.2.5 0.3353 940 579 1386 9.14015769186776e-38 6.97405421661774e-37 agent vehicle lipopolysaccharide agent untreated Type II IFN GDS715.2.10.18 GDS715.2.4.18 -0.3351 132 3836 3892 9.2530700107418e-103 2.63439222709571e-101 agent negative control pergolide methanesulfonate agent negative control a-methyl-L-p-tyrosine GDS1397.0.2 GDS2118.0.2 0.3348 590 2118 2573 1.98775186671187e-68 3.12360425634757e-67 agent untreated TNF-alpha disease state normal refractory anemia with ringed sideroblasts GDS2190.0.1 GDS2635.0.3 -0.3347 163 300 454 2.40361016600982e-13 7.3699040923518e-13 disease state control bipolar disorder disease state lobular control invasive ductal carcinoma GDS2250.0.3 GDS2649.2.5.1 0.3346 232 1267 1434 7.51071795100365e-39 5.91515272985211e-38 disease state normal basal-like cancer disease state uninfected early HIV infection GDS1392.0.1 GDS2021.0.2 0.3342 413 314 714 4.32388128829581e-20 1.84206464839017e-19 disease state normal rheumatoid arthritis, on methotrexate agent control nebivolol GDS2414.0.1.4 GDS2737.0.1.2 0.3341 129 279 401 6.52011803601292e-12 1.83520052117926e-11 agent control trophoblast conditioned medium disease state normal endometriosis GDS1850.0.1 GDS2200.0.1 0.3339 731 649 1324 7.60498948762264e-36 5.49885970443128e-35 disease state healthy carious disease state normal actinic keratosis GDS1615.0.2 GDS715.0.1.18 0.3338 3399 3116 5454 4.49804636542084e-142 2.16018865479998e-140 disease state normal Crohn's disease agent none positive control GDS715.1.2.18 GDS715.2.15.18 0.3337 2226 356 2457 5.56789356599535e-65 8.13126264759925e-64 agent negative control positive control agent negative control cyclazosin HCl GDS715.2.15.18 GDS715.2.4.18 0.3335 356 3836 4029 2.95477696225079e-105 8.72539202374135e-104 agent negative control cyclazosin HCl agent negative control a-methyl-L-p-tyrosine GDS1956.0.3 GDS715.0.4.18 -0.3332 4453 5001 7504 5.38172269471219e-194 4.4960098277318e-192 disease state normal amyotophic lateral sclerosis agent none a-methyl-L-p-tyrosine GDS2021.0.2 GDS2617.0.1 0.3332 314 119 421 2.25221602788555e-12 6.51516840317328e-12 agent control nebivolol disease state normal non-tumorigenic cancer cell GDS2021.0.2 GDS715.2.6.18 0.3331 314 582 874 4.3222582698144e-24 2.14667491759398e-23 agent control nebivolol agent negative control 16-ketoestradiol GDS1956.0.3 GDS715.2.9.18 0.3330 4453 3560 6668 2.17429597900076e-172 1.47347104753403e-170 disease state normal amyotophic lateral sclerosis agent negative control 5-fluorouridine GDS1543.0.1 GDS715.0.7.18 0.3327 466 136 600 5.6588111578617e-17 2.0936620127162e-16 agent control tumor necrosis factor agent none 4,5-dianilinophthalimide GDS2341.0.2.4 GDS715.0.6.18 0.3326 300 1378 1643 9.89395216439437e-44 8.86754084761985e-43 agent untreated Type II IFN agent none 16-ketoestradiol GDS2341.0.2.4 GDS2635.0.3 0.3321 300 300 587 1.40039461710946e-16 5.08649108033048e-16 agent untreated Type II IFN disease state lobular control invasive ductal carcinoma GDS1746.2.4.0 GDS2367.0.2.3 0.3317 222 282 495 3.5429460958524e-14 1.13819211018051e-13 disease state normal basaloid agent vehicle tamoxifen GDS1220.0.1.3 GDS1956.0.2 0.3314 1705 6836 7446 2.4596238396775e-190 1.98066978683909e-188 disease state normal malignant pleural mesothelioma disease state normal juvenile dermatomyositis GDS715.0.8.16 GDS715.2.15.18 0.3311 109 356 453 4.73853724545486e-13 1.42742301412316e-12 agent none 1,10-phenanthroline agent negative control cyclazosin HCl GDS1353.0.1.2 GDS1956.0.1 0.3309 1304 4393 5275 5.45808440118417e-135 2.40174876308113e-133 agent control dexamethasone disease state normal acute quadriplegic myopathy GDS2213.0.1 GDS715.0.1.18 0.3309 1016 3116 3790 1.59782167885489e-97 4.20824260890727e-96 agent untreated 5-aza-dC agent none positive control GDS1956.0.5 GDS651.0.1 -0.3305 2945 4221 5999 7.32702379209455e-153 4.01898569346717e-151 disease state normal fascioscapulohumeral muscular dystrophy disease state normal idiopathic dilated GDS2367.3.4.2 GDS2397.0.1 0.3305 691 580 1197 6.69801606949075e-32 4.31516818333661e-31 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal idiopathic myelofibrosis GDS1397.0.1 GDS715.2.4.18 -0.3303 1060 3836 4511 2.79686611372786e-115 9.5844352917496e-114 agent untreated HIV agent negative control a-methyl-L-p-tyrosine GDS1956.0.4 GDS715.0.8.16 -0.3302 1090 109 1190 1.15029722385155e-31 7.36298704098375e-31 disease state normal spastic paraplegia agent none 1,10-phenanthroline GDS2200.0.2 GDS2367.0.1.3 0.3296 1112 187 1258 2.92503631568373e-33 1.96074197302631e-32 disease state normal squamous cell carcinoma agent vehicle estradiol GDS1259.0.1 GDS266.0.1.2 -0.3296 2867 407 3150 1.04801143690836e-80 2.07084860284792e-79 disease state normal dermatomyositis disease state no atopy atopy GDS1062.2.3.0 GDS715.0.14.18 0.3292 483 141 622 3.46252188261311e-17 1.29482562479572e-16 disease state no metastasis metastasis agent none R-(-)-apomorphine HCl GDS1220.0.1.3 GDS1956.0.3 0.3286 1705 4453 5445 2.90958856678531e-137 1.3164394956988e-135 disease state normal malignant pleural mesothelioma disease state normal amyotophic lateral sclerosis GDS1376.2.3.1 GDS1392.0.1 0.3285 805 413 1195 1.82876624542217e-31 1.1632803208353e-30 disease state normal thrombocythemia disease state normal rheumatoid arthritis, on methotrexate GDS715.0.15.18 GDS715.1.2.18 0.3285 452 2226 2497 6.58947070347855e-64 9.41770630589824e-63 agent none cyclazosin HCl agent negative control positive control GDS1355.0.1 GDS2635.0.2 0.3284 433 263 682 1.29853568256706e-18 5.18825550790114e-18 disease state normal pancreatic ductal carcinoma disease state lobular control invasive lobular carcinoma GDS2250.0.1 GDS2649.2.5.1 0.3283 160 1267 1384 3.87790900323611e-36 2.82772908778288e-35 disease state normal non-basal-like cancer disease state uninfected early HIV infection GDS1956.0.3 GDS2142.0.2 0.3280 4453 604 4833 1.37629743299677e-121 5.14710116091311e-120 disease state normal amyotophic lateral sclerosis disease state normal severe cystic fibrosis GDS1220.0.1.3 GDS651.0.1 -0.3278 1705 4221 5267 3.64326305416865e-132 1.54530843699685e-130 disease state normal malignant pleural mesothelioma disease state normal idiopathic dilated GDS2164.0.1 GDS715.2.4.18 0.3278 1302 3836 4466 2.34108703281861e-112 7.68720738825004e-111 agent control SIV-Nef agent negative control a-methyl-L-p-tyrosine GDS2418.0.1 GDS2617.0.1 0.3278 2548 119 2626 8.0083495319038e-67 1.21516885733444e-65 disease state control vulvar intraepithelial neoplasia disease state normal non-tumorigenic cancer cell GDS2367.3.4.2 GDS2649.2.5.1 -0.3276 691 1267 1775 1.12522806580627e-45 1.05962957201453e-44 infection control adenovirus adenovirus carrying estrogen receptor beta disease state uninfected early HIV infection GDS1453.0.1 GDS2367.3.4.1 0.3268 432 266 671 3.64887835323886e-18 1.42815951692556e-17 agent untreated camptothecin infection control adenovirus adenovirus carrying estrogen receptor beta GDS1956.0.4 GDS715.0.14.18 -0.3266 1090 141 1221 9.64697053268683e-32 6.19015421572086e-31 disease state normal spastic paraplegia agent none R-(-)-apomorphine HCl GDS1453.0.1 GDS715.2.3.18 0.3264 432 266 687 1.61722167784246e-18 6.43296684013711e-18 agent untreated camptothecin agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2142.0.1 GDS2200.0.1 -0.3263 226 649 852 1.38147495151083e-22 6.4892100933141e-22 disease state normal mild cystic fibrosis disease state normal actinic keratosis GDS715.0.13.18 GDS715.2.3.18 -0.3256 274 266 519 2.78181800451162e-14 8.99210081660442e-14 agent none 8-(3-chlorostyryl) caffeine agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1971.0.2 GDS2255.3.4.1 0.3254 953 267 1139 1.68065034299478e-29 1.00797308447433e-28 disease state healthy complicated malaria agent untreated endotoxin GDS2213.0.3 GDS715.2.5.18 0.3251 1316 3040 3963 3.25250150156019e-98 8.64609939062529e-97 agent untreated 5-aza-dC plus TSA agent negative control sulmazole GDS1397.0.2 GDS715.0.15.18 -0.3249 590 452 1011 2.76792872756617e-26 1.4878272516112e-25 agent untreated TNF-alpha agent none cyclazosin HCl GDS2635.0.3 GDS715.0.4.18 -0.3249 300 5001 5224 1.07338084105463e-128 4.36289880597864e-127 disease state lobular control invasive ductal carcinoma agent none a-methyl-L-p-tyrosine GDS2200.0.1 GDS2611.0.3.9 0.3248 649 284 893 2.19457036404894e-23 1.06242684657902e-22 disease state normal actinic keratosis agent untreated IFN-gamma GDS1259.0.1 GDS2611.0.3.9 0.3247 2867 284 3023 3.65186720814812e-75 6.52287389162548e-74 disease state normal dermatomyositis agent untreated IFN-gamma GDS715.2.10.18 GDS715.2.9.18 0.3247 132 3560 3605 2.78109328027799e-89 6.4207551589365e-88 agent negative control pergolide methanesulfonate agent negative control 5-fluorouridine GDS1331.0.2 GDS715.2.10.18 0.3242 3398 132 3475 7.43645689386214e-86 1.61173776901581e-84 disease state normal symptomatic agent negative control pergolide methanesulfonate GDS2213.0.3 GDS715.2.3.18 0.3241 1316 266 1537 6.37883942400589e-39 5.03170738029902e-38 agent untreated 5-aza-dC plus TSA agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1439.0.2 GDS2418.0.1 0.3240 3178 2548 4657 2.8303524573891e-114 9.55248821893512e-113 disease state benign metastatic disease state control vulvar intraepithelial neoplasia GDS1392.0.1 GDS2057.0.2.3 0.3238 413 117 524 2.95848210449376e-14 9.54892594832723e-14 disease state normal rheumatoid arthritis, on methotrexate agent control RTI-018 GDS1956.0.6 GDS715.2.5.18 -0.3238 2160 3040 4683 9.37307981476409e-115 3.18788827052872e-113 disease state normal Emery-Dreifuss muscular dystrophy agent negative control sulmazole GDS1259.0.1 GDS505.0.1 0.3237 2867 2973 4833 2.71260090359935e-118 9.68586520888747e-117 disease state normal dermatomyositis disease state normal RCC GDS2164.0.1 GDS2617.0.1 0.3234 1302 119 1410 1.0952230133419e-35 7.885046692625e-35 agent control SIV-Nef disease state normal non-tumorigenic cancer cell GDS1956.0.3 GDS715.0.5.18 -0.3231 4453 4478 7233 2.19863115727544e-175 1.54082597930361e-173 disease state normal amyotophic lateral sclerosis agent none sulmazole GDS2617.0.2 GDS266.0.1.2 -0.3227 503 407 888 5.73571399221879e-23 2.73182802015392e-22 disease state normal tumorigenic cancer cell disease state no atopy atopy GDS2635.0.2 GDS2737.0.1.3 0.3226 263 739 974 5.01876462131161e-25 2.58256936373919e-24 disease state lobular control invasive lobular carcinoma disease state normal endometriosis GDS1353.0.1.2 GDS2341.0.2.4 -0.3225 1304 300 1544 1.05693240741177e-38 8.28922522712293e-38 agent control dexamethasone agent untreated Type II IFN GDS2021.0.2 GDS715.2.3.18 0.3223 314 266 570 3.03625273810773e-15 1.03330229777483e-14 agent control nebivolol agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1331.0.2 GDS1956.0.5 0.3221 3398 2945 5445 1.15718627679112e-131 4.88003248280284e-130 disease state normal symptomatic disease state normal fascioscapulohumeral muscular dystrophy GDS2200.0.1 GDS2341.0.3.4 0.3221 649 494 1105 4.30866911490482e-28 2.4632347851379e-27 disease state normal actinic keratosis agent untreated Types I and II IFNs GDS1282.0.1 GDS1574.8.9.11 -0.3220 1006 567 1532 2.70414197613908e-38 2.09654112118939e-37 disease state control Wilms' tumor agent control endotoxin GDS2142.0.2 GDS715.0.4.18 -0.3218 604 5001 5405 1.86057838883772e-130 7.74034214557866e-129 disease state normal severe cystic fibrosis agent none a-methyl-L-p-tyrosine GDS2414.0.1.4 GDS266.0.1.2 0.3215 129 407 533 2.78627234955154e-14 9.0059320659412e-14 agent control trophoblast conditioned medium disease state no atopy atopy GDS1353.0.1.2 GDS2118.0.2 -0.3214 1304 2118 3170 4.34478221028191e-77 8.05198198938963e-76 agent control dexamethasone disease state normal refractory anemia with ringed sideroblasts GDS2216.0.1.5 GDS715.2.13.18 0.3213 244 317 553 9.56809416621901e-15 3.17086320539239e-14 agent control LPS agent negative control 8-(3-chlorostyryl) caffeine GDS1956.0.5 GDS1956.0.9 0.3211 2945 2401 4617 3.26129471053492e-111 1.05115334311615e-109 disease state normal fascioscapulohumeral muscular dystrophy disease state normal Calpain 3 mutation GDS2213.0.1 GDS2213.0.2 0.3209 1016 385 1300 1.60534598772216e-32 1.05215549057325e-31 agent untreated 5-aza-dC agent untreated TSA GDS2367.0.1.3 GDS2397.0.1 -0.3209 187 580 725 7.93062859178165e-19 3.20086316376405e-18 agent vehicle estradiol disease state normal idiopathic myelofibrosis GDS2021.0.2 GDS2635.0.2 0.3205 314 263 565 5.79943615165876e-15 1.94444761911985e-14 agent control nebivolol disease state lobular control invasive lobular carcinoma GDS1956.0.4 GDS1956.0.9 0.3201 1090 2401 3119 3.0191366918825e-75 5.40210688301729e-74 disease state normal spastic paraplegia disease state normal Calpain 3 mutation GDS715.2.3.18 GDS715.2.9.18 0.3199 266 3560 3740 9.53374589339386e-90 2.22138998271946e-88 agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent negative control 5-fluorouridine GDS1746.2.4.0 GDS1956.0.5 -0.3197 222 2945 3097 1.54876488868624e-74 2.73025730580167e-73 disease state normal basaloid disease state normal fascioscapulohumeral muscular dystrophy GDS2617.0.2 GDS715.0.3.18 0.3197 503 592 1074 6.035108281129e-27 3.32254181408079e-26 disease state normal tumorigenic cancer cell agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1956.0.9 GDS2200.0.1 0.3195 2401 649 2863 5.94465029312536e-69 9.437900679592e-68 disease state normal Calpain 3 mutation disease state normal actinic keratosis GDS2164.0.1 GDS2367.0.1.3 -0.3194 1302 187 1452 8.58736537678895e-36 6.20073120997933e-35 agent control SIV-Nef agent vehicle estradiol GDS1956.0.5 GDS1956.0.7 0.3192 2945 1627 4082 2.42758639810179e-97 6.37399920400271e-96 disease state normal fascioscapulohumeral muscular dystrophy disease state normal Becker muscular dystrophy GDS1062.2.3.0 GDS266.0.1.2 -0.3192 483 407 879 2.8660946526589e-22 1.32998094345905e-21 disease state no metastasis metastasis disease state no atopy atopy GDS1615.0.2 GDS715.2.3.18 0.3191 3399 266 3555 5.85500754480884e-85 1.2482490552836e-83 disease state normal Crohn's disease agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2367.0.1.3 GDS2418.0.1 0.3191 187 2548 2620 4.33667902036711e-63 6.0844817698915e-62 agent vehicle estradiol disease state control vulvar intraepithelial neoplasia GDS1259.0.1 GDS715.1.2.18 0.3189 2867 2226 4358 1.35702283428461e-103 3.90831421428379e-102 disease state normal dermatomyositis agent negative control positive control GDS2142.0.2 GDS715.0.8.16 -0.3186 604 109 709 3.43709526957771e-18 1.34650568038792e-17 disease state normal severe cystic fibrosis agent none 1,10-phenanthroline GDS1331.0.2 GDS2367.3.4.1 -0.3184 3398 266 3546 2.29698342596574e-84 4.84801367711114e-83 disease state normal symptomatic infection control adenovirus adenovirus carrying estrogen receptor beta GDS2341.0.2.4 GDS715.2.6.18 0.3180 300 582 868 7.55607516281358e-22 3.44965435368606e-21 agent untreated Type II IFN agent negative control 16-ketoestradiol GDS1326.2.3.1 GDS2164.0.1 -0.3179 181 1302 1463 1.03462806052786e-35 7.45158142160448e-35 agent control E2 agent control SIV-Nef GDS1956.0.3 GDS2367.3.4.1 -0.3179 4453 266 4617 6.307445844113e-109 1.97067089394537e-107 disease state normal amyotophic lateral sclerosis infection control adenovirus adenovirus carrying estrogen receptor beta GDS1062.2.3.0 GDS2635.0.2 0.3179 483 263 736 9.56424116620372e-19 3.84709181624579e-18 disease state no metastasis metastasis disease state lobular control invasive lobular carcinoma GDS1062.2.3.0 GDS2341.0.2.4 -0.3174 483 300 776 1.27071577023579e-19 5.30547298584779e-19 disease state no metastasis metastasis agent untreated Type II IFN GDS1259.0.1 GDS2221.0.3 0.3173 2867 970 3455 1.15816998251859e-81 2.32978110047682e-80 disease state normal dermatomyositis agent untreated lipopolysaccharide GDS1392.0.2 GDS2118.0.2 0.3172 732 2118 2610 4.32038405795525e-62 5.93824426011841e-61 disease state normal myelodysplastic syndrome disease state normal refractory anemia with ringed sideroblasts GDS2142.0.2 GDS715.0.6.18 -0.3172 604 1378 1893 1.64208559441229e-45 1.53948183683091e-44 disease state normal severe cystic fibrosis agent none 16-ketoestradiol GDS715.0.7.18 GDS715.2.4.18 -0.3172 136 3836 3931 1.34236114188225e-92 3.27804983771228e-91 agent none 4,5-dianilinophthalimide agent negative control a-methyl-L-p-tyrosine GDS1331.0.2 GDS2432.0.1 -0.3171 3398 318 3626 1.67616865907835e-85 3.60643953412133e-84 disease state normal symptomatic disease state control pituitary adenoma predisposition GDS1376.2.3.1 GDS715.0.6.18 0.3171 805 1378 2108 1.87811644435824e-50 1.97224367160535e-49 disease state normal thrombocythemia agent none 16-ketoestradiol GDS2142.0.1 GDS2164.0.1 0.3171 226 1302 1506 1.58253716234604e-36 1.16533804643747e-35 disease state normal mild cystic fibrosis agent control SIV-Nef GDS1062.2.3.0 GDS715.2.9.18 -0.3170 483 3560 3969 2.35775517962389e-93 5.81482493040766e-92 disease state no metastasis metastasis agent negative control 5-fluorouridine GDS2341.0.3.4 GDS2635.0.3 0.3169 494 300 774 1.62365505641821e-19 6.7506854543201e-19 agent untreated Types I and II IFNs disease state lobular control invasive ductal carcinoma GDS1331.0.2 GDS2142.0.2 0.3167 3398 604 3840 3.33239432137241e-90 7.82854801830483e-89 disease state normal symptomatic disease state normal severe cystic fibrosis GDS1617.0.5 GDS266.0.1.2 0.3166 1981 407 2354 5.88196149675883e-56 7.05928382157233e-55 agent control MGd/50uM zinc disease state no atopy atopy GDS1956.0.5 GDS2142.0.1 -0.3162 2945 226 3122 1.92821803914186e-73 3.32718170719531e-72 disease state normal fascioscapulohumeral muscular dystrophy disease state normal mild cystic fibrosis GDS1353.0.1.2 GDS1453.0.1 -0.3161 1304 432 1682 2.41854797470172e-40 1.98232463548968e-39 agent control dexamethasone agent untreated camptothecin GDS1376.2.3.1 GDS1956.0.3 0.3161 805 4453 4910 2.30479065977713e-114 7.79066222046784e-113 disease state normal thrombocythemia disease state normal amyotophic lateral sclerosis GDS2200.0.1 GDS715.0.6.18 -0.3161 649 1378 1951 1.59399196801548e-46 1.5290275304245e-45 disease state normal actinic keratosis agent none 16-ketoestradiol GDS2200.0.2 GDS2611.0.2.9 0.3159 1112 640 1596 2.56809826789147e-38 1.99297220198454e-37 disease state normal squamous cell carcinoma agent untreated IL-1b GDS2057.0.2.4 GDS2367.0.1.3 0.3158 564 187 715 5.06369812634215e-18 1.96970570969876e-17 agent control RTI-018 agent vehicle estradiol GDS715.0.1.18 GDS715.0.7.18 0.3157 3116 136 3182 1.41782562989922e-74 2.50057479991397e-73 agent none positive control agent none 4,5-dianilinophthalimide GDS2697.0.1 GDS715.0.8.16 0.3154 6233 109 6268 8.62853852312392e-145 4.28278940881619e-143 disease state normal teratozoospermia agent none 1,10-phenanthroline GDS1956.0.4 GDS2142.0.2 -0.3152 1090 604 1648 2.46567109053108e-39 1.96691957973074e-38 disease state normal spastic paraplegia disease state normal severe cystic fibrosis GDS1355.0.1 GDS2617.0.1 0.3150 433 119 547 4.58404448123572e-14 1.46358133936583e-13 disease state normal pancreatic ductal carcinoma disease state normal non-tumorigenic cancer cell GDS2021.0.2 GDS715.0.11.18 0.3148 314 183 491 9.32968862913082e-13 2.76186989992814e-12 agent control nebivolol agent none scopolamine methyl bromide GDS1574.8.9.11 GDS715.0.10.18 0.3145 567 158 694 2.12975212069373e-17 8.04855629445721e-17 agent control endotoxin agent none pergolide methanesulfonate GDS1956.0.1 GDS651.0.1 -0.3143 4393 4221 6910 2.90078022680722e-158 1.68284911601396e-156 disease state normal acute quadriplegic myopathy disease state normal idiopathic dilated GDS2341.0.2.4 GDS2367.3.4.1 0.3142 300 266 559 2.83793190501002e-14 9.16886660852532e-14 agent untreated Type II IFN infection control adenovirus adenovirus carrying estrogen receptor beta GDS2142.0.1 GDS2737.0.1.3 0.3141 226 739 948 3.76116830698048e-23 1.8047264776403e-22 disease state normal mild cystic fibrosis disease state normal endometriosis GDS2341.0.2.4 GDS715.2.3.18 0.3138 300 266 563 2.48712238200771e-14 8.06304016663418e-14 agent untreated Type II IFN agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1062.2.3.0 GDS1376.2.3.1 -0.3136 483 805 1271 2.10771767490958e-30 1.29839831451664e-29 disease state no metastasis metastasis disease state normal thrombocythemia GDS1062.2.3.0 GDS2021.0.2 -0.3135 483 314 788 1.97555305413281e-19 8.18526182800621e-19 disease state no metastasis metastasis agent control nebivolol GDS1062.2.3.0 GDS2617.0.2 -0.3131 483 503 971 1.58180991950226e-23 7.70187084297325e-23 disease state no metastasis metastasis disease state normal tumorigenic cancer cell GDS2414.0.1.4 GDS715.2.6.18 -0.3129 129 582 703 1.96647382560695e-17 7.44356872724304e-17 agent control trophoblast conditioned medium agent negative control 16-ketoestradiol GDS1355.0.1 GDS1392.0.1 0.3128 433 413 831 2.55179262853013e-20 1.09744178529289e-19 disease state normal pancreatic ductal carcinoma disease state normal rheumatoid arthritis, on methotrexate GDS2057.0.1.4 GDS715.0.1.18 -0.3128 292 3116 3286 1.65886436838628e-75 2.98239725722138e-74 agent control DHT agent none positive control GDS1259.0.1 GDS2216.0.1.5 0.3125 2867 244 3022 1.89441331111178e-69 3.0307519508357e-68 disease state normal dermatomyositis agent control LPS GDS2142.0.2 GDS2852.0.1.5 0.3124 604 538 1105 1.93434574057492e-26 1.04596437244836e-25 disease state normal severe cystic fibrosis agent control IL-13 GDS1956.0.4 GDS715.0.15.18 -0.3122 1090 452 1494 3.91474559742687e-35 2.77265129077567e-34 disease state normal spastic paraplegia agent none cyclazosin HCl GDS2200.0.1 GDS2617.0.2 0.3121 649 503 1114 1.3634651644975e-26 7.40939513736709e-26 disease state normal actinic keratosis disease state normal tumorigenic cancer cell GDS1282.0.1 GDS2250.0.3 0.3120 1006 232 1197 1.9510448474885e-28 1.12919230258248e-27 disease state control Wilms' tumor disease state normal basal-like cancer GDS2367.0.2.3 GDS2418.0.1 0.3118 282 2548 2656 5.65291539605844e-61 7.58359925294813e-60 agent vehicle tamoxifen disease state control vulvar intraepithelial neoplasia GDS1746.2.4.0 GDS2418.0.1 0.3115 222 2548 2695 1.01043208273256e-61 1.37761882968927e-60 disease state normal basaloid disease state control vulvar intraepithelial neoplasia GDS2164.0.1 GDS651.0.1 -0.3111 1302 4221 5122 2.40503624375328e-115 8.25271461424668e-114 agent control SIV-Nef disease state normal idiopathic dilated GDS1574.8.9.13 GDS2737.0.1.3 -0.3109 1931 739 2577 7.27004839813876e-59 9.32952892554648e-58 agent control endotoxin disease state normal endometriosis GDS1543.0.1 GDS715.2.5.18 0.3108 466 3040 3337 1.20062408473019e-75 2.16486744021904e-74 agent control tumor necrosis factor agent negative control sulmazole GDS2414.0.1.4 GDS715.0.3.18 -0.3108 129 592 712 2.07086637926655e-17 7.83082604210855e-17 agent control trophoblast conditioned medium agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.0.14.18 GDS715.2.4.18 -0.3106 141 3836 3929 1.26670093809603e-88 2.88893157283036e-87 agent none R-(-)-apomorphine HCl agent negative control a-methyl-L-p-tyrosine GDS2142.0.1 GDS2611.0.3.9 -0.3103 226 284 486 2.62414277591056e-12 7.55883337633976e-12 disease state normal mild cystic fibrosis agent untreated IFN-gamma GDS2428.0.1.3 GDS715.0.6.18 0.3097 181 1378 1531 2.17974904520487e-35 1.55512822041953e-34 agent untreated 5-aza-dC agent none 16-ketoestradiol GDS2341.0.3.4 GDS715.0.6.18 0.3095 494 1378 1813 1.51976119441508e-41 1.28653521022682e-40 agent untreated Types I and II IFNs agent none 16-ketoestradiol GDS2221.1.3 GDS2649.3.5.0 0.3094 940 229 1106 5.79698476220847e-26 3.08137747505276e-25 agent vehicle lipopolysaccharide disease state uninfected chronic HIV infection GDS1397.0.1 GDS715.0.4.18 -0.3093 1060 5001 5548 2.74212855938838e-123 1.046346543534e-121 agent untreated HIV agent none a-methyl-L-p-tyrosine GDS1956.0.1 GDS2164.0.1 0.3092 4393 1302 5266 4.84571783709373e-117 1.70417282505885e-115 disease state normal acute quadriplegic myopathy agent control SIV-Nef GDS2250.0.3 GDS715.2.4.18 -0.3083 232 3836 4012 4.4025309454385e-89 1.0129260869183e-87 disease state normal basal-like cancer agent negative control a-methyl-L-p-tyrosine GDS1956.0.5 GDS715.0.4.18 -0.3082 2945 5001 6780 3.978497956796e-149 2.08354593710907e-147 disease state normal fascioscapulohumeral muscular dystrophy agent none a-methyl-L-p-tyrosine GDS1956.0.3 GDS2737.0.1.4 -0.3080 4453 416 4699 8.29904509677001e-104 2.39555631231197e-102 disease state normal amyotophic lateral sclerosis disease state normal endometriosis GDS1375.0.2 GDS2250.0.1 0.3079 4896 160 4934 7.85882690249697e-109 2.45040521827756e-107 disease state normal malignant melanoma disease state normal non-basal-like cancer GDS2213.0.1 GDS715.0.5.18 0.3078 1016 4478 5099 2.48307444767848e-112 8.14648866672272e-111 agent untreated 5-aza-dC agent none sulmazole GDS2200.0.1 GDS2367.3.4.2 -0.3075 649 691 1307 5.07216569666295e-30 3.08713543617661e-29 disease state normal actinic keratosis infection control adenovirus adenovirus carrying estrogen receptor beta GDS1956.0.2 GDS715.0.9.18 0.3068 6836 3151 8161 2.07177320149879e-177 1.4822832984202e-175 disease state normal juvenile dermatomyositis agent none 5-fluorouridine GDS1331.0.2 GDS2153.0.1 0.3067 3398 1932 4626 2.456232456505e-101 6.8300866497074e-100 disease state normal symptomatic disease state normal dermatomyositis GDS266.0.1.2 GDS715.0.1.18 0.3067 407 3116 3420 2.1184733484743e-75 3.80116195476369e-74 disease state no atopy atopy agent none positive control GDS2164.0.1 GDS715.0.5.18 0.3064 1302 4478 5111 1.55018221648423e-111 5.0248188761774e-110 agent control SIV-Nef agent none sulmazole GDS1259.0.1 GDS1617.0.5 0.3063 2867 1981 4164 3.70460029734799e-91 8.83231577487553e-90 disease state normal dermatomyositis agent control MGd/50uM zinc GDS1926.0.2.4 GDS2362.6.7.2.5 -0.3061 119 797 892 8.3810300029137e-21 3.67597086470339e-20 agent control LTD4 agent untreated chloroguine treated GDS1220.0.1.3 GDS2200.0.2 0.3060 1705 1112 2599 1.84003377722889e-57 2.28713041254238e-56 disease state normal malignant pleural mesothelioma disease state normal squamous cell carcinoma GDS1617.0.5 GDS2635.0.3 -0.3055 1981 300 2256 6.07741023302029e-50 6.31012494510734e-49 agent control MGd/50uM zinc disease state lobular control invasive ductal carcinoma GDS1376.2.3.1 GDS651.0.1 -0.3054 805 4221 4722 1.69114779752838e-102 4.79262148560598e-101 disease state normal thrombocythemia disease state normal idiopathic dilated GDS1397.0.1 GDS715.0.15.18 -0.3052 1060 452 1461 7.17061337046995e-33 4.74654789274422e-32 agent untreated HIV agent none cyclazosin HCl GDS1050.2.3.0 GDS715.2.4.18 0.3046 1874 3836 5045 8.64902371174037e-109 2.69515349922045e-107 agent untreated valproic acid agent negative control a-methyl-L-p-tyrosine GDS1062.2.3.0 GDS715.0.6.18 0.3045 483 1378 1803 5.42221031016933e-40 4.40460282762791e-39 disease state no metastasis metastasis agent none 16-ketoestradiol GDS1326.2.3.1 GDS715.2.4.18 0.3042 181 3836 3967 1.03229675106387e-85 2.22981144657865e-84 agent control E2 agent negative control a-methyl-L-p-tyrosine GDS1392.0.1 GDS2118.0.3 0.3042 413 976 1309 1.98778086896741e-29 1.188840935614e-28 disease state normal rheumatoid arthritis, on methotrexate disease state normal refractory anemia with excess blasts GDS2341.0.3.4 GDS2635.0.2 0.3042 494 263 745 2.04612690731504e-17 7.73955656306064e-17 agent untreated Types I and II IFNs disease state lobular control invasive lobular carcinoma GDS1956.0.2 GDS715.2.4.18 -0.3040 6836 3836 8419 1.66992926698551e-179 1.21971605580895e-177 disease state normal juvenile dermatomyositis agent negative control a-methyl-L-p-tyrosine GDS1331.0.1 GDS715.2.10.18 0.3039 1070 132 1188 8.36939529389225e-27 4.58111357018081e-26 disease state normal presymptomatic agent negative control pergolide methanesulfonate GDS2200.0.1 GDS715.2.6.18 -0.3039 649 582 1195 5.94487443070061e-27 3.27345010365782e-26 disease state normal actinic keratosis agent negative control 16-ketoestradiol GDS2635.0.3 GDS2649.2.5.0 0.3037 300 404 692 3.12602535883224e-16 1.11659613031474e-15 disease state lobular control invasive ductal carcinoma disease state uninfected early HIV infection GDS2190.0.1 GDS2852.0.1.5 -0.3035 163 538 694 2.96984620480782e-16 1.06181990884245e-15 disease state control bipolar disorder agent control IL-13 GDS2021.0.2 GDS715.0.6.18 0.3034 314 1378 1659 1.15171794327617e-36 8.50698181897167e-36 agent control nebivolol agent none 16-ketoestradiol GDS1956.0.4 GDS2164.0.1 0.3033 1090 1302 2245 5.5065737402642e-49 5.59407305726713e-48 disease state normal spastic paraplegia agent control SIV-Nef GDS1050.2.3.0 GDS715.0.4.18 0.3031 1874 5001 5999 1.09159591540751e-127 4.38141685405657e-126 agent untreated valproic acid agent none a-methyl-L-p-tyrosine GDS715.0.1.18 GDS715.0.6.18 0.3027 3116 1378 3766 1.21600009955451e-80 2.40094189979587e-79 agent none positive control agent none 16-ketoestradiol GDS2200.0.1 GDS2418.0.1 0.3026 649 2548 2920 6.86340568491022e-63 9.59109456802345e-62 disease state normal actinic keratosis disease state control vulvar intraepithelial neoplasia GDS1956.0.4 GDS2367.0.2.3 0.3025 1090 282 1339 9.84293593111113e-30 5.9403416442834e-29 disease state normal spastic paraplegia agent vehicle tamoxifen GDS2200.0.2 GDS2250.0.1 0.3021 1112 160 1201 9.16354993293089e-27 5.01064018609155e-26 disease state normal squamous cell carcinoma disease state normal non-basal-like cancer GDS1220.0.1.3 GDS1956.0.5 0.3017 1705 2945 4166 2.08345374955876e-88 4.73484575302543e-87 disease state normal malignant pleural mesothelioma disease state normal fascioscapulohumeral muscular dystrophy GDS2164.0.1 GDS715.2.3.18 0.3017 1302 266 1510 3.79479052861326e-33 2.53438617130614e-32 agent control SIV-Nef agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.2.15.18 GDS715.2.6.18 0.3014 356 582 895 2.98542682288391e-20 1.28064259488307e-19 agent negative control cyclazosin HCl agent negative control 16-ketoestradiol GDS266.0.1.2 GDS715.1.2.18 0.3012 407 2226 2562 7.06866129943844e-55 8.27013415173891e-54 disease state no atopy atopy agent negative control positive control GDS1956.0.5 GDS2191.0.1 -0.3006 2945 942 3608 3.05979691532852e-76 5.58123068519382e-75 disease state normal fascioscapulohumeral muscular dystrophy disease state control bipolar disorder GDS2239.0.1 GDS2635.0.2 0.3006 332 263 581 1.34240707675149e-13 4.18329247856173e-13 agent control hepatitis C virus core protein disease state lobular control invasive lobular carcinoma GDS1746.2.4.0 GDS715.2.6.18 -0.3005 222 582 791 5.69304391043138e-18 2.20971111419927e-17 disease state normal basaloid agent negative control 16-ketoestradiol GDS1331.0.1 GDS715.2.3.18 -0.3003 1070 266 1311 9.9743556558383e-29 5.83374902131966e-28 disease state normal presymptomatic agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2142.0.2 GDS2239.0.1 0.3003 604 332 929 8.16540061876566e-21 3.58282338549085e-20 disease state normal severe cystic fibrosis agent control hepatitis C virus core protein GDS1574.8.9.13 GDS2649.3.5.1 0.3003 1931 599 2376 1.03484851945141e-50 1.09413012427757e-49 agent control endotoxin disease state uninfected chronic HIV infection GDS2367.3.4.1 GDS715.2.13.18 0.3001 266 317 573 2.1724954492232e-13 6.68148927388674e-13 infection control adenovirus adenovirus carrying estrogen receptor beta agent negative control 8-(3-chlorostyryl) caffeine